86 results on '"Robert G. Selker"'
Search Results
2. Selected human leukocyte antigen class II polymorphisms and risk of adult glioma
- Author
-
Jay S. Loeffler, Laurie Burdette, Robert Dubrow, Robert G. Selker, Peter McL. Black, William R. Shapiro, Howard A. Fine, Alina V. Brenner, Bryan A. Bassig, and Peter D. Inskip
- Subjects
Adult ,Male ,musculoskeletal diseases ,Inverse Association ,Immunology ,Human leukocyte antigen ,Biology ,Logistic regression ,Article ,immune system diseases ,HLA-DQ Antigens ,Glioma ,medicine ,HLA-DQ beta-Chains ,Humans ,Immunology and Allergy ,Genetic Predisposition to Disease ,Allele ,HLA-DR Antigen ,Aged ,Polymorphism, Genetic ,HLA-DQ Antigen ,Brain Neoplasms ,Case-control study ,nutritional and metabolic diseases ,HLA-DR Antigens ,Middle Aged ,medicine.disease ,Neurology ,Case-Control Studies ,Female ,Neurology (clinical) ,HLA-DRB1 Chains - Abstract
Few studies have examined the relationship between human leukocyte antigen (HLA) polymorphisms and adult glioma, particularly at class II loci. We evaluated the association between selected HLA class II polymorphisms and adult glioma in a large, hospital-based case-control study, using unconditional logistic regression. DQB1*06 (OR = 1.67, 95% CI = 1.17–2.39) and DRB1*13 (OR = 1.69, 95% CI = 1.08–2.64) alleles were associated with an increased risk of glioma, while the DQB1*05 allele showed an inverse association (OR = 0.63, 95% CI = 0.43–0.93). These results, which were of borderline significance once controlled for the false discovery rate, suggest a potential role for the DQB1*06 , DQB1*05 , and DRB1*13 alleles in glioma susceptibility.
- Published
- 2011
3. DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma
- Author
-
Jay S. Loeffler, Martha S. Linet, Amy Hutchinson, Nathaniel Rothman, Peter McL. Black, William R. Shapiro, Peter D. Inskip, Howard A. Fine, Sara M. Wichner, Preetha Rajaraman, and Robert G. Selker
- Subjects
Adult ,Male ,Cancer Research ,Adolescent ,DNA Repair ,Single-nucleotide polymorphism ,Biology ,Polymorphism, Single Nucleotide ,Young Adult ,XRCC1 ,MUTYH ,Glioma ,Meningeal Neoplasms ,otorhinolaryngologic diseases ,medicine ,Humans ,Genetic Predisposition to Disease ,Aged ,Aged, 80 and over ,Brain Neoplasms ,Adult Meningioma ,Neuroma, Acoustic ,Middle Aged ,medicine.disease ,Proliferating cell nuclear antigen ,Oncology ,Case-Control Studies ,Basic and Translational Investigations ,Cancer research ,biology.protein ,ERCC2 ,Female ,Neurology (clinical) ,Meningioma ,ERCC4 - Abstract
Although the etiology of primary brain tumors is largely unknown, prior studies suggest that DNA repair polymorphisms may influence risk of glioma. Altered DNA repair is also likely to affect the risk of meningioma and acoustic neuroma, but these tumors have not been well studied. We estimated the risk of glioma (n = 362), meningioma (n = 134), and acoustic neuroma (n = 69) in non-Hispanic whites with respect to 36 single nucleotide polymorphisms from 26 genes involved in DNA repair in a hospital-based, case-control study conducted by the National Cancer Institute. We observed significantly increased risk of meningioma with the T variant of GLTSCR1 rs1035938 (OR(CT/TT) = 3.5; 95% confidence interval: 1.8-6.9; P(trend) .0006), which persisted after controlling for multiple comparisons (P = .019). Significantly increased meningioma risk was also observed for the minor allele variants of ERCC4 rs1800067 (P(trend) .01); MUTYH rs3219466 (P(trend) .02), and PCNA rs25406 (P(trend) .03). The NBN rs1805794 minor allele variant was associated with decreased meningioma risk (P(trend) .006). Risk of acoustic neuroma was increased for the ERCC2 rs1799793 (P(trend) .03) and ERCC5 rs17655 (P(trend) .05) variants and decreased for the PARP1 rs1136410 (P(trend) .03). Decreased glioma risk was observed with the XRCC1 rs1799782 variant (P(trend) .04). Our results suggest that common DNA repair variants may affect the risk of adult brain tumors, especially meningioma.
- Published
- 2009
4. Occupational exposure to magnetic fields and the risk of brain tumors
- Author
-
Martha S. Linet, Mustafa Dosemeci, Joseph Coble, Jay S. Loeffler, Robert G. Selker, William R. Shapiro, Peter McL. Black, Aaron Blair, Howard A. Fine, Patricia A. Stewart, Joseph D. Bowman, and Peter D. Inskip
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Job-exposure matrix ,Logistic regression ,Electromagnetic Fields ,Occupational Exposure ,Surveys and Questionnaires ,Glioma ,Internal medicine ,medicine ,Humans ,Aged ,Lifetime exposure ,Brain Neoplasms ,business.industry ,Case-control study ,Odds ratio ,Middle Aged ,medicine.disease ,Surgery ,Oncology ,Case-Control Studies ,Basic and Translational Investigations ,Female ,Neurology (clinical) ,Occupational exposure ,business ,Glioblastoma - Abstract
We investigated the association between occupational exposure to extremely low-frequency magnetic fields (MFs) and the risk of glioma and meningioma. Occupational exposure to MF was assessed for 489 glioma cases, 197 meningioma cases, and 799 controls enrolled in a hospital-based case–control study. Lifetime occupational history questionnaires were administered to all subjects; for 24% of jobs, these were supplemented with job-specific questionnaires, or “job modules,” to obtain information on the use of electrically powered tools or equipment at work. Job-specific quantitative estimates for exposure to MF in milligauss were assigned using a previously published job exposure matrix (JEM) with modification based on the job modules. Jobs were categorized as ≤1.5 mG, >1.5 to 1.5 mG; (3) cumulative lifetime exposure; and (4) average lifetime exposure. Odds ratios (ORs) were calculated using unconditional logistic regression with adjustment for the age, gender, and hospital site. The job modules increased the number of jobs with exposure ≥3.0 mG from 4% to 7% relative to the JEM. No statistically significant elevation in ORs or trends in ORs across exposure categories was observed using four different exposure metrics for the three tumor types analyzed. Occupational exposure to MFs assessed using job modules was not associated with an increase in the risk for glioma, glioblastoma, or meningioma among the subjects evaluated in this study.
- Published
- 2009
5. Genetic variation in insulin-like growth factors and brain tumor risk
- Author
-
Robert G. Selker, Howard A. Fine, Peter D. Inskip, Amy Hutchinson, Nathaniel Rothman, Stefan Lönn, Jay S. Loeffler, Peter McL. Black, and William R. Shapiro
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,IGFBP3 ,Biology ,Polymorphism, Single Nucleotide ,Somatomedins ,Glioma ,Internal medicine ,medicine ,Humans ,Genetic Predisposition to Disease ,Receptor ,Aged ,Insulin-like growth factor 1 receptor ,Aged, 80 and over ,Brain Neoplasms ,Cell growth ,Growth factor ,Cancer ,Middle Aged ,medicine.disease ,nervous system diseases ,Endocrinology ,Oncology ,Case-Control Studies ,Basic and Translational Investigations ,Cancer research ,Female ,Neurology (clinical) ,Adult stem cell - Abstract
The insulin-like growth factor (IGF) system comprises two ligands (IGF-1 and IGF-2), the IGF-1 and IGF-2 receptors, six binding proteins (IGFBP-1 to -6), and various IGFBP-related peptides.1 IGF-1 is the major physiological mediator of the effect of growth hormone and therefore has a strong influence on cell proliferation and differentiation. It also inhibits apoptosis by blocking initiation of the apoptotic pathway.1 The IGF-1 receptor (IGF-1R) mediates the action of IGF-1 and is involved in oncogenic transformation processes.1 IGFBPs modulate the interaction between IGF-1 and IGF-1R but also have independent effects on cell growth.1–3 IGFBP-3 has an inhibitory effect on IGF-1 activity and also acts as an apoptotic agent.1 IGFBP-3 also has been recognized to exhibit a number of growth-promoting effects. Experimental studies have shown that alterations in IGF function can influence cellular transformation and tumor cell proliferation. IGF1, IGF2, and IGF1R genes have all been reported to be overexpressed in glioma and meningioma as well as in a wide range of other human cancers, including breast, leukemia, lung, thyroid, and prostate.4 IGFs, together with their receptors and binding proteins, have been reported to be associated with cancer risk.5,6 Epidemiological studies have suggested that genetic variation in IGF1, IGF1R, and IGFBP3 may be related to breast, prostate, and colorectal cancer risk.7–10 In vitro studies have demonstrated that IGF receptors and binding proteins promote mitogenesis and differentiation in glial cells, oligodendrocytes, neuronal cells, adult stem cells, and brain explants and regulate axon myelination.4 Furthermore, observations in the literature suggest that IGF gene pathways show similar expression and functional features during fetal development and tumorigenesis.11 There is, however, little epidemiologic data concerning the possible involvement of IGF signaling in the development of brain tumors in humans. A recent small prospective study indicated an inverse association between glioma and IGF-1 serum levels.12 We hypothesized that polymorphisms in IGF genes are risk factors for glioma and meningioma. To test the hypothesis, we examined associations with several IGF gene variants in the context of a case-control study.
- Published
- 2008
6. Polymorphisms in Apoptosis and Cell Cycle Control Genes and Risk of Brain Tumors in Adults
- Author
-
Robert G. Selker, Nathaniel Rothman, Preetha Rajaraman, Stephen J. Chanock, Sophia S. Wang, William R. Shapiro, Jay S. Loeffler, Peter McL. Black, Howard A. Fine, Peter D. Inskip, and Merideth Brown
- Subjects
Male ,Oncology ,Epidemiology ,Apoptosis ,Risk Factors ,CDKN2A ,Genes, Tumor Suppressor ,Aged, 80 and over ,Caspase 8 ,biology ,Brain Neoplasms ,Proto-Oncogene Proteins c-mdm2 ,Exons ,Glioma ,Neuroma, Acoustic ,Middle Aged ,Cell cycle ,Female ,Meningioma ,Adult ,Cyclin-Dependent Kinase Inhibitor p21 ,medicine.medical_specialty ,Adolescent ,Brain tumor ,Single-nucleotide polymorphism ,Protein Serine-Threonine Kinases ,Polymorphism, Single Nucleotide ,Cyclin H ,Cyclin D ,Cyclins ,Internal medicine ,otorhinolaryngologic diseases ,medicine ,Humans ,PTEN ,neoplasms ,CHEK2 ,Aged ,business.industry ,Genes, p16 ,PTEN Phosphohydrolase ,Genetic Variation ,Odds ratio ,Genes, p53 ,medicine.disease ,Genes, cdc ,Checkpoint Kinase 2 ,Haplotypes ,Case-Control Studies ,Checkpoint Kinase 1 ,Immunology ,biology.protein ,business ,Protein Kinases - Abstract
Despite the potential importance of the cell cycle and apoptosis pathways in brain tumor etiology, little has been published regarding brain tumor risk associated with common gene variants in these pathways. Using data from a hospital-based case-control study conducted by the National Cancer Institute between 1994 and 1998, we evaluated risk of glioma (n = 388), meningioma (n = 162), and acoustic neuroma (n = 73) with respect to 12 single nucleotide polymorphisms from 10 genes involved in apoptosis and cell cycle control: CASP8, CCND1, CCNH, CDKN1A, CDKN2A, CHEK1, CHEK2, MDM2, PTEN, and TP53. We observed significantly decreased risk of meningioma with the CASP8 Ex14-271A>T variant [odds ratio (OR)AT, 0.8; 95% confidence interval (95% CI), 0.5-1.2; ORAA, 0.5; 95% CI, 0.3-0.9; Ptrend = 0.03] and increased risk of meningioma with the CASP8 Ex13+51G>C variant (ORGC, 1.4; 95% CI, 0.9-2.1; ORCC, 3.6; 95% CI, 1.0-13.1; Ptrend = 0.04). The CT haplotype of the two CASP8 polymorphisms was associated with significantly increased risk of meningioma (OR, 1.7; 95% CI, 1.1-2.6), but was not associated with risk of glioma or acoustic neuroma. The CCND1 Ex4-1G>A variant was associated with increased risk for glioma, and the Ex8+49T>C variant of CCNH was associated with increased risk of glioma and acoustic neuroma. The MDM2 Ex12+162A>G variant was associated with significantly reduced risk of glioma. Our results suggest that common variants in the CASP8, CCND1, CCNH, and MDM2 genes may influence brain tumor risk. Future research in this area should include more detailed coverage of genes in the apoptosis/cell cycle control pathways. (Cancer Epidemiol Biomarkers Prev 2007;16(8):1655–61)
- Published
- 2007
7. Lead, Genetic Susceptibility, and Risk of Adult Brain Tumors
- Author
-
Robert G. Selker, Preetha Rajaraman, Howard A. Fine, Brian S. Schwartz, Martha S. Linet, Patricia A. Stewart, Meredith Yeager, Peter D. Inskip, Nathanial Rothman, S H Zahrn, Jonathan M. Samet, William R. Shapiro, Peter McL. Black, and Jay S. Loeffler
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Pathology ,Adolescent ,Genotype ,Epidemiology ,Biology ,Bioinformatics ,Occupational medicine ,Lead (geology) ,Occupational Exposure ,Glioma ,Internal medicine ,medicine ,Genetic predisposition ,Humans ,Genetic Predisposition to Disease ,Aged ,Exposure assessment ,Aged, 80 and over ,Brain Neoplasms ,business.industry ,Arizona ,Case-control study ,Odds ratio ,Middle Aged ,Pennsylvania ,medicine.disease ,Confidence interval ,Lead ,Massachusetts ,Case-Control Studies ,Female ,Meningioma ,business - Abstract
Background: Although few etiologic factors for brain tumors have been identified, limited data suggest that lead may increase the risk of brain tumors, particularly meningioma. The ALAD G177C polymorphism affects the toxicokinetics of lead and may confer genetic susceptibility to adverse effects of lead exposure. Methods: We examined occupational exposure to lead and risk of brain tumors in a multisite, hospital-based, case-control study of 489 patients with glioma, 197 with meningioma, and 799 non-cancer controls frequency matched on hospital, age, sex, race/ethnicity, and residential proximity to hospital. ALAD genotype was assessed by a Taqman assay for 355 glioma patients, 151 meningioma patients, and 505 controls. Exposure to lead was estimated using a rigorous questionnaire-based exposure assessment strategy incorporating lead measurement and other occupational data abstracted from published articles and reports. Results: Increased risk of meningioma with occupational lead exposure (estimated by odds ratios and 95% confidence intervals) was most apparent in individuals with the ALAD2 variant allele, for whom risk increased from 1.1 (0.3-4.5) to 5.6 (0.7-45.5) and 12.8 (1.4-120.8) for estimated cumulative lead exposures of 1 to 49 μg/m3-y, 50 to 99 μg/m3-y, and ≥100 μg/m3-y, respectively, compared with unexposed individuals (two-sided P trend = 0.06). This relationship became stronger after excluding occupational lead exposures characterized by a low confidence level or occurring in the 10 years before meningioma diagnosis. Occupational lead exposure was not associated with glioma risk. Conclusions: Although our results indicate that lead may be implicated in meningioma risk in genetically susceptible individuals, these results need to be interpreted with caution given the small numbers of exposed cases with a variant genotype. (Cancer Epidemiol Biomarkers Prev 2006;15(12):2514–20)
- Published
- 2006
8. Self-reported Electrical Appliance Use and Risk of Adult Brain Tumors
- Author
-
Peter D. Inskip, Robert E. Tarone, Robert G. Selker, William R. Shapiro, Peter McL. Black, Ruth A. Kleinerman, Martha S. Linet, Elizabeth E. Hatch, and Howard A. Fine
- Subjects
Adult ,Male ,medicine.medical_specialty ,Neoplasms, Radiation-Induced ,Adolescent ,Epidemiology ,Brain tumor ,Audiology ,Electromagnetic Fields ,Heating pad ,Risk Factors ,Recall bias ,Glioma ,Meningeal Neoplasms ,Odds Ratio ,medicine ,Humans ,Risk factor ,Household Articles ,Brain Neoplasms ,business.industry ,Case-control study ,Neuroma, Acoustic ,Odds ratio ,Middle Aged ,medicine.disease ,Confidence interval ,Surgery ,Case-Control Studies ,Female ,Meningioma ,business - Abstract
Electrical appliances produce the highest intensity exposures to residential extremely low frequency electromagnetic fields. The authors investigated whether appliances may be associated with adult brain tumors in a hospital-based case-control study at three centers in the United States from 1994 to 1998. A total of 410 glioma, 178 meningioma, and 90 acoustic neuroma cases and 686 controls responded to a self-administered questionnaire about 14 electrical appliances. There was little evidence of association between brain tumors and curling iron, heating pad, vibrating massager, electric blanket, heated water bed, sound system, computer, television, humidifier, microwave oven, and electric stove. Ever use of hair dryers was associated with glioma (odds ratio = 1.7, 95% confidence interval: 1.1, 2.5), but there was no evidence of increasing risk with increasing amount of use. In men, meningioma was associated with electric shaver use (odds ratio = 10.9, 95% confidence interval: 2.3, 50), and odds ratios increased with cumulative minutes of use, although they were based on only two nonexposed cases. Recall bias for appliances used regularly near the head or chance may provide an alternative explanation for the observed associations. Overall, results indicate that extremely low frequency electromagnetic fields from commonly used household appliances are unlikely to increase the risk of brain tumors.
- Published
- 2005
9. Meningioma and schwannoma risk in adults in relation to family history of cancer
- Author
-
Robert G. Selker, Peter D. Inskip, William R. Shapiro, Martha S. Linet, Peter McL. Black, Deirdre A. Hill, and Howard A. Fine
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Brain tumor ,Schwannoma ,Meningioma ,Breast cancer ,Risk Factors ,Internal medicine ,Meningeal Neoplasms ,otorhinolaryngologic diseases ,medicine ,Humans ,Genetic Predisposition to Disease ,Family history ,Aged ,Brain Neoplasms ,business.industry ,Age Factors ,Cancer ,Odds ratio ,Middle Aged ,medicine.disease ,Surgery ,Oncology ,Case-Control Studies ,Relative risk ,Basic and Translational Investigations ,Female ,Neurology (clinical) ,business ,Neurilemmoma - Abstract
Relatively little is known about factors that contribute to the development of meningioma and vestibular schwannoma, two intracranial nervous system tumors. We evaluated the risk of these tumors in relation to family history of malignant or benign tumors. Incident cases of meningioma (n = 197) or schwannoma (n = 96) were identified at three U.S. referral hospitals between June 1994 and August 1998. Controls (n = 799) admitted to the same hospitals for nonmalignant conditions were matched to cases on age, sex, race/ethnicity, hospital, and proximity of residence to hospital. We found that risk of meningioma was increased among persons reporting a family history of a benign brain tumor (odds ratio [OR], 4.5; 95% confidence interval [CI], 1.0–21.0; n = 5) or melanoma (OR, 4.2; 95% CI, 1.2–15.0; n = 5). A family history of breast cancer was associated with an elevated meningioma risk among participants aged 18 to 49 years (OR, 3.9; 95% CI, 1.4 –11.0; n = 8) but a reduced risk among older respondents (OR, 0.2; 95% CI, 0.1–0.7; n = 3). Family history of cancer did not differ between schwannoma cases and controls, although the statistical power to detect associations was limited. Some relative risk estimates were based on a small number of observations and may have arisen by chance. Inheritance of predisposing genes, shared environmental factors, or both within families with a history of benign brain tumors, melanoma, or possibly breast cancer may be related to altered meningioma risk.
- Published
- 2004
10. Season of birth and risk of brain tumors in adults
- Author
-
Robert G. Selker, Martha S. Linet, Howard A. Fine, Peter McL. Black, Alina V. Brenner, Peter D. Inskip, and William R. Shapiro
- Subjects
Adult ,Male ,Risk ,Vitamin ,Pediatrics ,medicine.medical_specialty ,Season of birth ,Physiology ,Comorbidity ,Functional Laterality ,vitamin D deficiency ,Autoimmune Diseases ,chemistry.chemical_compound ,Sex Factors ,Meningeal Neoplasms ,Odds Ratio ,medicine ,Vitamin D and neurology ,Humans ,Risk factor ,Prenatal vitamins ,Pregnancy ,Brain Neoplasms ,business.industry ,Arizona ,Parturition ,Case-control study ,Glioma ,Middle Aged ,Pennsylvania ,medicine.disease ,chemistry ,Case-Control Studies ,Female ,Seasons ,Neurology (clinical) ,Meningioma ,business ,Boston - Abstract
Recent studies demonstrated an excess of winter births in children with brain tumors and in adults with various neurologic or psychiatric diseases relative to the general population.To investigate a possible association between month of birth and risk of brain tumors in adults using data from a large, hospital-based case-control study.Cases were patients with incident glioma (n = 489) or meningioma (n = 197) diagnosed at hospitals in Boston, MA, Phoenix, AZ, and Pittsburgh, PA. Controls (n = 799) were patients hospitalized for a variety of nonmalignant conditions and frequency matched to cases by hospital, age, sex, race/ethnicity, and distance of residence from hospital. Odds ratios (ORs) were calculated using multivariate unconditional logistic regression allowing for cyclic variation in risk with month of birth.A relationship between month of birth and risk of adult glioma and meningioma was found, best described by a 12-month periodic function with peaks in February and January and troughs in August and July. The association between month of birth and risk of glioma differed significantly by handedness, with left-handed and ambidextrous subjects born during late fall through early spring being at particularly high risk of adult glioma as compared with those born at other times of the year.These findings suggest the importance of seasonally varying exposures during the pre- or postnatal period in the development of brain tumors in adults.
- Published
- 2004
11. Sociodemographic indicators and risk of brain tumours
- Author
-
Robert G. Selker, Martha S. Linet, Timothy C. Wilcosky, William R. Shapiro, Jay S. Loeffler, Peter D. Inskip, Robert E. Tarone, Elizabeth E. Hatch, Howard A. Fine, and Peter McL. Black
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Pathology ,Adolescent ,Epidemiology ,Acoustic neuroma ,Meningioma ,Age Distribution ,Residence Characteristics ,Glioma ,Internal medicine ,otorhinolaryngologic diseases ,Humans ,Medicine ,Risk factor ,neoplasms ,Aged ,Insurance, Health ,Marital Status ,Brain Neoplasms ,business.industry ,Incidence ,Incidence (epidemiology) ,Arizona ,Case-control study ,General Medicine ,Middle Aged ,Pennsylvania ,medicine.disease ,nervous system diseases ,Religion ,Case-Control Studies ,Income ,Educational Status ,Marital status ,Female ,business ,Boston - Abstract
To better understand patterns of occurrence or diagnosis of brain tumours in different segments of the population, we evaluated associations between sociodemographic variables and the relative incidence of brain tumours as part of a multi-faceted case-control study.The study was conducted at hospitals in three US cities between 1994 and 1998. In all, 489 glioma cases (354 high-grade, 135 low-grade), 197 meningioma cases, 96 acoustic neuroma cases, and 799 controls admitted to the same hospitals for any of a variety of non-neoplastic diseases or conditions were enrolled and interviewed. Logistic regression was used to estimate odds ratios (OR), calculate 95% CI, and test for trends.The OR showed significant positive associations with household income for low-grade glioma, meningioma, and acoustic neuroma, but not for high-grade glioma. Positive associations were observed with level of education for low-grade glioma and acoustic neuroma, but not for high-grade glioma or meningioma. Jewish religion was associated with a significantly elevated risk for meningioma (OR = 4.3; 95% CI: 2.0-9.0). Being single at the time of tumour diagnosis or enrolment was associated with significantly reduced risks for meningioma (OR = 0.4; 95% CI: 0.3-0.6) and low- or high-grade glioma (OR = 0.6; 95% CI: 0.5-0.8), but not for acoustic neuroma.Associations with sociodemographic variables varied considerably among the different subtypes of brain tumour, including between low-grade and high-grade glioma. The general pattern was for associations with indicators of affluence and education to be stronger for tumours that tend to grow more slowly and have less catastrophic effects, although the evidence was mixed for meningioma. We cannot isolate the specific factors underlying the observed associations, but intrapopulation differences in the completeness or timing of diagnosis may have played a role. There is less opportunity for such influences to operate for the rapidly progressing, high-grade gliomas than for more slowly growing tumours.
- Published
- 2003
12. [Untitled]
- Author
-
A J De Roos, Robert G. Selker, Patricia A. Stewart, Howard A. Fine, Timothy C. Wilcosky, Peter McL. Black, Martha S. Linet, Ellen F. Heineman, William R. Shapiro, Peter D. Inskip, and Mustafa Dosemeci
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Public health ,Incidence (epidemiology) ,Case-control study ,Odds ratio ,medicine.disease ,Confidence interval ,Oncology ,Occupational hygiene ,Glioma ,Epidemiology ,medicine ,business ,Demography - Abstract
Objective: Previous studies have observed increased glioma incidence associated with employment in the petroleum and electrical industries, and in farming. Several other occupations have also been associated with increased risk, but with inconsistent results. We evaluated associations between occupational title and glioma incidence in adults. Methods: Cases were 489 patients with glioma diagnosed from 1994 to 1998 at three United States hospitals. Controls were 799 patients admitted to the same hospitals for non-malignant conditions. An experienced industrial hygienist grouped occupations that were expected to have similar tasks and exposures. The risk of adult glioma was evaluated for those subjects who ever worked in an occupational group for at least six months, those who worked longer than five years in the occupation, and those with more than ten years latency since starting work in the occupation. Results: Several occupational groups were associated with increased glioma incidence for having ever worked in the occupation, including butchers and meat cutters (odds ratio [OR] = 2.4; 95% confidence limits [CL]: 1.0, 6.0), computer programmers and analysts (OR = 2.0; 95% CL: 1.0, 3.8), electricians (OR = 1.8; 95% CL: 0.8, 4.1), general farmers and farmworkers (OR = 2.5; 95% CL: 1.4, 4.7), inspectors, checkers, examiners, graders, and testers (OR = 1.5; 95% CL: 0.8, 2.7), investigators, examiners, adjustors, and appraisers (OR = 1.7; 95% CL: 0.8, 3.7), physicians and physician assistants (OR = 2.4; 95% CL: 0.8, 7.2), and store managers (OR = 1.6; 95% CL: 0.8, 3.1), whereas occupation as a childcare worker was associated with decreased glioma incidence (OR = 0.4; 95% CL: 0.2, 0.9). These associations generally persisted when the subjects worked longer than five years in the occupation, and for those with more than ten years latency since starting to work in the occupation. Conclusions: This is our first analysis of occupation and will guide future exposure-specific assessments.
- Published
- 2003
13. The Brain Tumor Cooperative Group NIH Trial 87-01: A Randomized Comparison of Surgery, External Radiotherapy, and Carmustine versus Surgery, Interstitial Radiotherapy Boost, External Radiation Therapy, and Carmustine
- Author
-
Mark G. Malkin, Kathleen R. Lamborn, Stephen M. Bloomfield, Sylvan B. Green, Fred H. Hochberg, Vincent C. Arena, Julian Wu, Susan M. Chang, James T. Robertson, Margaret S. Blackwood, Robert E. Albright, Melvin Deutsch, Robert G. Selker, Peter McL. Black, James T. Rutka, Jeffrey J. Olson, William R. Shapiro, John Mealey, Gene H. Barnett, Raymond Sawaya, Mitchel S. Berger, Jay S. Loeffler, Joseph M. Piepmeier, John H. Neal, Penny K. Sneed, Peter C. Burger, Emile M. Hiesiger, Philip H. Gutin, and John C. Van Gilder
- Subjects
medicine.medical_specialty ,Chemotherapy ,Carmustine ,genetic structures ,business.industry ,medicine.medical_treatment ,Brachytherapy ,Brain tumor ,medicine.disease ,Surgery ,law.invention ,Radiation therapy ,Clinical trial ,Randomized controlled trial ,law ,medicine ,Combined Modality Therapy ,Neurology (clinical) ,business ,medicine.drug - Abstract
OBJECTIVE The objective of the Brain Tumor Cooperative Group NIH Trial 87-01 trial was to investigate the effect of additional implanted radiation therapy in newly diagnosed patients with pathologically confirmed malignant gliomas.METHODS The study involved a randomized comparison of surgery, extern
- Published
- 2002
14. History of allergies and autoimmune diseases and risk of brain tumors in adults
- Author
-
Howard A. Fine, William R. Shapiro, Peter D. Inskip, Peter McL. Black, Martha S. Linet, Robert G. Selker, and Alina V. Brenner
- Subjects
Adult ,Male ,Cancer Research ,Allergy ,medicine.medical_specialty ,Adolescent ,Autoimmune Diseases ,Diabetes Complications ,Risk Factors ,Glioma ,Immunopathology ,Internal medicine ,Epidemiology ,Hypersensitivity ,Odds Ratio ,medicine ,Humans ,Risk factor ,Aged ,Autoimmune disease ,Brain Neoplasms ,business.industry ,Case-control study ,Neuroma, Acoustic ,Odds ratio ,Middle Aged ,medicine.disease ,Asthma ,Logistic Models ,Oncology ,Immunology ,Income ,Educational Status ,Female ,Meningioma ,business - Abstract
To explore a possible influence of the immune system in the development of brain tumors, we evaluated the relationship between history of allergies and autoimmune diseases and risk of brain tumors within a large, hospital-based case-control study. Cases (n = 782) were patients recently diagnosed with glioma (n = 489), meningioma (n = 197) or acoustic neuroma (n = 96) at hospitals in Boston, Phoenix and Pittsburgh (USA). Controls (n =799) were patients hospitalized for a variety of nonmalignant conditions and frequency-matched to cases by hospital, age, sex, race/ethnicity and distance of residence from hospital. Research nurses collected data by personal interview of patients. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using unconditional logistic regression. There was a significant inverse association between glioma and history of any allergies (OR = 0.67, 95% CI = 0.52-0.86) or autoimmune diseases (OR = 0.49, 95% CI = 0.35-0.69). No significant associations were evident for meningioma or acoustic neuroma with history of any allergies. An inverse association was observed between meningioma and history of autoimmune diseases (OR = 0.59, 95% CI = 0.38-0.92). There was a suggestion of interaction between allergies and autoimmune diseases on risk of glioma (p = 0.06), with subjects having both conditions being at lowest risk (OR = 0.24, 95% CI = 0.14-0.42). Among the specific conditions, asthma and diabetes showed the most consistent associations (OR = 0.63, 95% CI = 0.43-0.92 and OR = 0.44, 95% CI = 0.27-0.70, respectively). Our results add to evidence that persons with allergies or autoimmune diseases are at reduced risk of glioma. The basis of the associations is not clear, but they might imply a role of immunologic factors in the development of brain tumors. Published 2002 Wiley-Liss, Inc.
- Published
- 2002
15. Study Design for a Case Control Investigation of Cellular Telephones and Other Risk Factors for Brain Tumors in Adults
- Author
-
D. Parry, Peter D. Inskip, Howard A. Fine, Elizabeth E. Hatch, Timothy C. Wilcosky, Jay S. Loeffler, Patricia A. Stewart, Mustafa Dosemeci, Nathanial Rothman, Linet, R.G. Ziegler, J.D. Boice Jr., Ellen F. Heineman, D.J. Watson, P. McL. Black, William R. Shapiro, and Robert G. Selker
- Subjects
Pediatrics ,medicine.medical_specialty ,Radiation ,Radiological and Ultrasound Technology ,business.industry ,Incidence (epidemiology) ,Public Health, Environmental and Occupational Health ,Case-control study ,Acoustic neuroma ,Cancer ,General Medicine ,medicine.disease ,Surgery ,medicine ,Etiology ,Radiology, Nuclear Medicine and imaging ,Medical history ,Family history ,Risk factor ,business - Abstract
The aetiology of brain tumours is poorly understood. Due, in part, to public concern about a postulated relationship between the use of cellular telephones or other increasingly prevalent environmental exposures and the incidence of brain cancer in adults, the National Cancer Institute is collaborating with three US hospitals in a comprehensive case-control study of malignant and benign brain tumours. Factors under consideration include use of cellular phones and other wireless communication devices, workplace exposures to chemical agents and electromagnetic fields, dietary factors, family history of tumours, genetic determinants of susceptibility, home appliance use, reproductive history and hormonal exposures, viruses, medical and dental exposure to ionising radiation, and other aspects of medical history. Approximately 800 newly diagnosed brain tumour cases and 800 controls were enrolled at hospitals in Boston, Phoenix and Pittsburgh from 1994 to 1998. Cases include all adults (age ≥ 18 y) newly diagnosed with a histologically confirmed intracranial glioma, histologically confirmed intracranial meningioma or acoustic neuroma. Controls are patients admitted to the same hospitals as the eases, and treated for any of a variety of non-malignant conditions. Key features of the study include its large size, the emphasis on rapid ascertainment of incident cases and interview of study subjects rather than surrogate respondents, the use of detailed, job-specific questions developed by industrial hygienists to ascertain occupational exposures, and the storage of blood samples for future evaluation of inherited susceptibility, biomarkers of exposure and gene-environment interactions.
- Published
- 1999
16. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
- Author
-
R Morawetz, K Black, N. A. Vick, Michael B. Sisti, Henry Brem, P Muller, Steven Brem, Peter C. Burger, S.C Schold, G Mohr, Michael D. Walker, Robert G. Selker, and Steven Piantadosi
- Subjects
Carmustine ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Hazard ratio ,Placebo-controlled study ,General Medicine ,Placebo ,law.invention ,Surgery ,Clinical trial ,Randomized controlled trial ,law ,medicine ,business ,Survival rate ,medicine.drug - Abstract
Chemotherapy for brain tumours has been limited because of difficulty in achieving adequate exposure to the tumour without systemic toxicity. We have developed a method for local sustained release of chemotherapeutic agents by their incorporation into biodegradable polymers. Implantation of the drug-impregnated polymer at the tumour site allows prolonged local exposure with minimal systemic exposure. We conducted a randomised, placebo-controlled, prospective study to evaluate the effectiveness of biodegradable polymers impregnated with carmustine to treat recurrent malignant gliomas. In 27 medical centres, 222 patients with recurrent malignant brain tumours requiring re-operation were randomly assigned to receive surgically implanted biodegradable polymer discs with or without 3.85% carmustine. Randomisation balanced the treatment groups for all of the prognostic factors examined. Median survival of the 110 patients who received carmustine polymers was 31 weeks compared with 23 weeks for the 112 patients who received only placebo polymers (hazard ratio = 0.67, p = 0.006, after accounting for the effects of prognostic factors). Among patients with glioblastoma, 6-month survival in those treated with carmustine-polymer discs was 50% greater than in those treated with placebo (mortality = 32 of 72 [44%] vs 47 of 73 [64%], p = 0.02). There were no clinically important adverse reactions related to the carmustine polymer, either in the brain or systemically. Interstitial chemotherapy delivered with polymers directly to brain tumours at the time of surgery seems to be a safe and effective treatment for recurrent malignant gliomas.
- Published
- 1995
17. Correlation of Thallium-201 Single Photon Emission Computed Tomography and Survival after Treatment Failure in Patients with Glioblastoma Multiforme
- Author
-
Stanley J. Grossman, Judith M. Joyce, Frank T. Vertosick, and Robert G. Selker
- Subjects
Adult ,Male ,medicine.medical_treatment ,chemistry.chemical_element ,Single-photon emission computed tomography ,Central nervous system disease ,Glioma ,Biopsy ,medicine ,Humans ,Prospective Studies ,Treatment Failure ,Radiation Injuries ,Tomography, Emission-Computed, Single-Photon ,medicine.diagnostic_test ,Brain Neoplasms ,business.industry ,Brain ,Radiotherapy Dosage ,Magnetic resonance imaging ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Survival Rate ,Radiation therapy ,Thallium Radioisotopes ,chemistry ,Positron emission tomography ,Thallium ,Female ,Surgery ,Neurology (clinical) ,Cranial Irradiation ,Neoplasm Recurrence, Local ,Glioblastoma ,Nuclear medicine ,business ,Follow-Up Studies - Abstract
After initial radiotherapy for an intracranial malignant glioma, the majority of patients return at a later date with a recurrent, enhancing mass on computed tomography or magnetic resonance imaging. This mass represents either recurrent tumor, radionecrosis, or a combination of the two. The relative proportion of live versus dead tumor cells is difficult to determine from surgical specimens of another biopsy, although this has been the preferred method of assessing such "failed" patients. Recently, attention has turned to tomographic images of metabolic markers, i.e., positron emission tomography and thallium-201 (Tl-201) single photon emission computed tomography, as noninvasive methods of assessing relative tumor viability. To assess whether Tl-201 uptake in vivo can be used as a prognostic indicator in patients with glioblastoma multiforme, we measured the ratio of Tl-201 uptake in tumor to Tl-201 uptake in myocardium (T/C ratio) in 16 patients at the point of treatment "failure" and followed all the patients until they died. All patients died of neurological causes, and 11 of the 16 patients had documented viable tumor recurrence. There was a significant negative correlation between the T/C ratio at failure and the time interval between failure and death (r = -0.602, P = 0.014). Patients with T/C ratios of less than 0.3 lived an average of 13 months, whereas patients with T/C ratios of more than 0.3 lived an average of only 4 months.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1994
18. The Treatment of Intracranial Malignant Gliomas Using Orally Administered Tamoxifen Therapy
- Author
-
Robert G. Selker, Ian F. Pollack, Frank T. Vertosick, and Vincent C. Arena
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Internal medicine ,Medicine ,Surgery ,Tamoxifen therapy ,Neurology (clinical) ,business - Published
- 1992
19. Survival of Patients with Well-Differentiated Astrocytomas Diagnosed in The Era of Computed Tomography
- Author
-
Frank T. Vertosick, Vincent C. Arena, and Robert G. Selker
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Disease ,Astrocytoma ,Biopsy ,medicine ,Humans ,Papilledema ,Survival rate ,Craniotomy ,medicine.diagnostic_test ,Brain Neoplasms ,business.industry ,Radiotherapy Dosage ,Middle Aged ,medicine.disease ,Debulking ,Surgery ,Survival Rate ,Radiation therapy ,Cell Transformation, Neoplastic ,Female ,Neurology (clinical) ,medicine.symptom ,Glioblastoma ,Tomography, X-Ray Computed ,business ,Follow-Up Studies - Abstract
We report 25 verified cases of well-differentiated cerebral astrocytomas in adults treated between 1978 and 1988. All patients were diagnosed by computed tomographic (CT); scans, with 5 undergoing a craniotomy for debulking and 20 undergoing a biopsy alone. The median survival for the entire group was 8.2 years, the longest survival yet reported for a series of patients with these tumors. A review of the literature suggests that the longer survival observed in more recent series is the result of the earlier diagnosis of tumors afforded by modern brain imaging. Twenty of our patients presented with seizures in the absence of any other focal findings and would probably not have had a biopsy in the era before CT scans until their tumors had progressed. Only 8% of our patients had papilledema at the time of presentation, in contrast to almost half of the patients with low-grade astrocytomas reported before 1975, supporting the hypothesis that patients in the CT era are diagnosed earlier. None of our patients died from progressive low-grade disease. One patient died from a squamous cell cancer, and 7 died as a consequence of their tumors dedifferentiating into a more malignant astrocytoma or glioblastoma multiforme, with a median time of approximately 5 years after the diagnosis. Our findings, together with the available data in the literature, suggest that death from a focal low-grade astrocytoma, in the absence of malignant degeneration, may be a rare event. Consequently, future therapeutic efforts should be targeted at preventing dediffer-entiation. The use of radiotherapy in this series of patients did not make a significant impact upon either the time to dedifferentiation or the time to death, but the numbers are small. Given the potential long-term detrimental effect of radiotherapy, the use of this treatment modality must be re-evaluated in the light of the earlier diagnosis and longer natural survival of the patient with an astrocytoma diagnosed in the CT era. Moreover, given the longer survival we observed in a patient population diagnosed predominantly by a biopsy alone, the necessity for radical surgery may also need to be reviewed. In view of the evolving nature of this patient population, much of the older literature on astrocytomas may have little relevance in advising and treating the “modern” patient with an astrocytoma.
- Published
- 1991
20. Oxidative response gene polymorphisms and risk of adult brain tumors
- Author
-
Preetha Rajaraman, Robert G. Selker, Nathaniel Rothman, Martha S. Linet, Peter D. Inskip, William R. Shapiro, Howard A. Fine, Jay S. Loeffler, Amy Hutchinson, and Peter McL. Black
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Pathology ,Adolescent ,Brain tumor ,SOD2 ,Single-nucleotide polymorphism ,medicine.disease_cause ,Gastroenterology ,Polymorphism, Single Nucleotide ,Internal medicine ,Glioma ,medicine ,otorhinolaryngologic diseases ,Humans ,Genetic Predisposition to Disease ,Aged ,Aged, 80 and over ,business.industry ,Brain Neoplasms ,Superoxide Dismutase ,Case-control study ,Odds ratio ,Middle Aged ,medicine.disease ,Catalase ,PON1 ,Oxidative Stress ,Oncology ,Case-Control Studies ,Basic and Translational Investigations ,Female ,Neurology (clinical) ,business ,Oxidative stress - Abstract
Oxidative stress is believed to play a key role in tumor formation. Although this mechanism could be especially pertinent for brain tumors given the high oxygen consumption of the brain, very little has been published regarding brain tumor risk with respect to genes mediating oxidative stress. Using data from non-Hispanic whites in a hospital-based case-control study conducted by the National Cancer Institute between 1994 and 1998, we evaluated risk of glioma (n = 362), meningioma (n = 134), and acoustic neuroma (n = 69) compared to noncancer controls (n = 494) with respect to nine single nucleotide polymorphisms from seven genes involved in oxidative stress response (CAT, GPX1, NOS3, PON1, SOD1, SOD2, and SOD3). We observed increased risk of glioma (odds ratio [OR]CT/CC = 1.3; 95% confidence interval [95% CI], 1.0–1.7) and meningioma (ORCT/CC = 1.7; 95% CI, 1.1–2.7) with the C variant of SOD3 rs699473. There was also indication of increased acoustic neuroma risk with the SOD2 rs4880 Ala variant (ORCT/CC = 2.0; 95% CI, 1.0–4.2) and decreased acoustic neuroma risk with the CAT rs1001179 T allele variant (ORCT/TT = 0.6; 95% CI, 0.3–1.0). These relationships persisted when major groups of disease controls were excluded from the analysis. Our results suggest that common variants in the SOD2, SOD3, and CAT genes may influence brain tumor risk.
- Published
- 2008
21. Brain Stem and Spinal Metastases of Supratentorial Glioblastoma Multiforme: A Clinical Series
- Author
-
Frank T. Vertosick and Robert G. Selker
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Autopsy ,Disease ,Metastasis ,Basal (phylogenetics) ,medicine ,Humans ,Cerebellar Neoplasms ,Myelography ,Spinal Neoplasms ,medicine.diagnostic_test ,business.industry ,Brain Neoplasms ,Incidence (epidemiology) ,Magnetic resonance imaging ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Surgery ,Radiation therapy ,Female ,Neurology (clinical) ,business ,Glioblastoma ,Tomography, X-Ray Computed ,Brain Stem - Abstract
Although the spread of supratentorial glioblastoma multiforme to the brain stem and spine has been extensively described in published autopsy series, information on the diagnosis, treatment, and subsequent clinical course of patients manifesting symptoms of glioblastomatous dissemination ante mortem remains scant. We report a series of 11 patients having the signs and symptoms of neuraxis dissemination of supratentorial glioblastoma multiforme. All patients had radiographic documentation of metastases by either contrast-enhanced myelograms or enhanced magnetic resonance imaging scans. Ten presented with spinal involvement, whereas one presented with lower cranial neuropathies secondary to diffuse involvement of the basal cisterns. The mean age of the patients was 38.5 years, and the mean time interval between diagnosis of intracranial disease and diagnosis of metastases was 14.1 months. After diagnosis of tumor spread, subsequent mean survival time was 2.8 months. All patients received additional radiotherapy to the areas of metastasis, but the clinical response to radiotherapy was quite poor. This study confirms previous reports in the literature suggesting that metastases occur in younger patients and in patients with extended survival. The findings suggest that the relatively infrequent clinical incidence of the symptomatic spread of glioblastoma multiforme, as compared with the frequent incidental discovery of such spread at autopsy, may be the result of the limited survival of the affected patients, and not due to the biology of the tumor.
- Published
- 1990
22. The Risk and Efficacy of Anticoagulant Therapy in the Treatment of Thromboembolic Complications in Patients with Primary Malignant Brain Tumors
- Author
-
Frank T. Vertosick, Robert G. Selker, Hans Moosa, and Eric Altschuler
- Subjects
Surgery ,Neurology (clinical) - Abstract
Twenty-three patients with malignant glial neoplasms were treated with anticoagulant therapy for thromboembolic complications. Fifteen patients had deep vein thrombosis alone, and 8 patients had both deep vein thrombosis and pulmonary embolism. Serum prothrombin times were maintained at 1.25 times control for an average of 5.8 months per patient, for a total patient exposure to warfarin therapy of 132 patient-months (11 patient-years). Only 1 patient suffered a recurrent pulmonary embolism, and this occurred during an episode of gastrointestinal bleeding, when anticoagulant therapy had to be discontinued prematurely. All patients were followed with serial computed tomographic or magnetic resonance imaging scans, and no patient showed radiographic evidence of intratumoral hemorrhage either during or after warfarin therapy. One patient, who died from a large recurrent glioblastoma, was found at autopsy to have scattered foci of intratumoral hemorrhage. This series, together with a review of the available literature, suggests that oral anticoagulant therapy is both a safe and effective means of treating thromboembolic complications in patients with residual malignant glial tumors.
- Published
- 1990
23. Personal hair dye use and risks of glioma, meningioma, and acoustic neuroma among adults
- Author
-
Robert G. Selker, Jay S. Loeffler, Shelia Hoar Zahm, Elizabeth C. Bluhm, William R. Shapiro, Peter D. Inskip, Peter McL. Black, and Howard A. Fine
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Adolescent ,Epidemiology ,Brain tumor ,Hair Dyes ,Acoustic neuroma ,Logistic regression ,Risk Assessment ,Beauty Culture ,Meningioma ,visual_art.color ,Risk Factors ,Glioma ,otorhinolaryngologic diseases ,medicine ,Humans ,Aged ,Aged, 80 and over ,business.industry ,Brain Neoplasms ,Arizona ,Odds ratio ,Environmental Exposure ,Neuroma, Acoustic ,Middle Aged ,Pennsylvania ,medicine.disease ,Dermatology ,Confidence interval ,Brown hair ,visual_art ,Case-Control Studies ,Female ,sense organs ,business ,Boston - Abstract
Previous studies have suggested an association of personal hair dye use with bladder and hematopoietic cancers. Risks for brain tumors are not well understood. The authors investigated associations between use of synthetic hair dyes and risk of brain tumors in a hospital-based case-control study. The study included adults newly diagnosed with glioma (n = 489), meningioma (n = 197), or acoustic neuroma (n = 96) between 1994 and 1998 at three urban US hospitals and 799 controls. Odds ratios were estimated and 95% confidence intervals were calculated using unconditional logistic regression. Detailed exposure histories were obtained by interview. There was no consistent pattern of elevated odds ratios for glioma, meningioma, or acoustic neuroma with use or prolonged use of permanent, semipermanent, temporary, or gradual hair dyes. Although use of permanent brown hair dye for 20 or more years was associated with glioma among women, the estimate was imprecise (odds ratio = 3.8, 95% confidence interval: 1.2, 12.5) and was based on just 13 exposed cases; thus, this could be a chance finding. Overall, there was little consistent evidence for an association of synthetic hair dye use with glioma, meningioma, or acoustic neuroma. However, prolonged use of dark-colored permanent dyes warrants further investigation given the high prevalence of hair dyeing.
- Published
- 2006
24. Variation in genes relevant to aromatic hydrocarbon metabolism and the risk of adult brain tumors
- Author
-
Peter McL. Black, Merideth Brown, Anneclaire J. De Roos, Howard A. Fine, Douglas A. Bell, Robert G. Selker, Peter D. Inskip, William R. Shapiro, Gary S. Pittman, and Nathaniel Rothman
- Subjects
Adult ,Male ,Cancer Research ,Genotype ,Clinical Investigations ,EPHX1 ,Hydrocarbons, Aromatic ,chemistry.chemical_compound ,Risk Factors ,Cytochrome P-450 CYP1A1 ,NAD(P)H Dehydrogenase (Quinone) ,Humans ,Genetic Predisposition to Disease ,Carcinogen ,Aged ,chemistry.chemical_classification ,Epoxide Hydrolases ,Chemistry ,Brain Neoplasms ,Glioma ,Neuroma, Acoustic ,Middle Aged ,Aryl Hydrocarbon Hydroxylases ,Oncology ,Biochemistry ,Microsomal epoxide hydrolase ,Cytochrome P-450 CYP1B1 ,Pyrene ,Female ,Neurology (clinical) ,Aromatic hydrocarbon ,Meningioma - Abstract
Both genetic and environmental factors are likely to be important causes of primary brain tumors. The few clues about brain tumor etiology indicate that certain occupations involving exposure to polycyclic aromatic hydrocarbons (PAHs)2 or other aromatic hydrocarbons may be associated with increased risk (Inskip, P.D., et al., 1995), most notably work in the petroleum industry (Carozza et al., 2000; Demers et al., 1991; Preston-Martin, 1989; Thomas et al., 1986, 1987); however, multiple exposures in implicated occupations limit possible conclusions about aromatic hydrocarbons. Smoking, a major source of aromatic hydrocarbon exposure, has been associated with brain tumor incidence in several studies (Burch et al., 1987; Lee et al., 1997), but not consistently so (Inskip, P.D., et al., 1995), and sometimes only among certain subgroups (Efird et al., 2004; Phillips et al., 2005). It is possible that underlying variability in genes responsible for biotransformation and metabolism of aromatic hydrocarbons could hinder the consistency of studies of chemical exposures. For this reason, it may be illuminating to study the association of variants in genes involved in aromatic hydrocarbon metabolism with the risk of brain tumors. The conversion of PAHs to DNA-reactive products depends on a complex series of biotransformations. In the case of benzo[a]pyrene, transformation events include oxidation by cytochrome P-450 enzymes (such as CYP1A1) to create the active benzo[a]pyrene epoxide (Pelkonen and Nebert, 1982; Shimada et al., 1996), hydration by microsomal epoxide hydrolase (EPHX1) to the less toxic benzo[a]pyrene diol, oxidation by P-450 enzymes (such as CYP1B1) to the highly carcinogenic benzo[a]pyrene diol epoxide, detoxification of benzo[a]-pyrene and benzo[a]pyrene diol epoxide by glutathione S-transferases (such as GSTM1, GSTT1, and possibly GSTM3) by addition of reduced glutathione to electrophilic compounds (Omiecinski et al., 2000; Strange et al., 2001), and reduction of oxidative potential of quinones derived from benzo[a]pyrene diol by NAD(P)H:quinone oxidoreductase 1 (NQO1) (Palackal et al., 2002; Pastorelli et al., 1998; Ross et al., 2000). There is evidence from animal experiments that NAD(P)H protects from PAH-induced carcinogenicity; this protection is thought to operate through decreases in quinone-induced DNA adduct formation and DNA mutagenicity, including that induced by benzo[a]pyrene quinine (Joseph and Jaiswal, 1998; Long et al., 2001). In a previous report, we presented case-control study results for some genes known to be involved in metabolism of PAHs or other potential carcinogens, namely, CYP2E1, GSTM1, and GSTT1 (De Roos et al., 2003). For the current investigation, we selected several additional candidate genes related to PAHs or other aromatic hydrocarbons; all of the selected metabolic genes exhibit sequence variation that may relate to function. Substitution of valine with isoleucine in exon 7 of CYP1A1 results in a variant (I462V) with increased arylhydrocarbon hydroxylase activity (Cosma et al., 1993; Crofts et al., 1994; Kiyohara et al., 1996, 1998; Taioli et al., 1995). The functional significance of a CYP1B1 variant, V432L, is not well known; however, some studies suggest that the valine product results in higher catalytic activity toward some PAH dihydrodiols relative to leucine (Shimada et al., 1999), possibly leading to increased levels of reactive intermediates. The GSTM3 gene has a three-base-pair deletion in intron 6, and the two alleles are referred to as GSTM3*A and GSTM3*B (Inskip, A., et al., 1995; Strange et al., 2001). This deletion creates a recognition motif (-aagata-) for the YY1 transcription factor which could potentially affect detoxification activity by GSTM3*B (Strange et al., 2001). The EPHX1 variant Y113H has demonstrated increased activity in vitro but not in vivo (Hassett et al., 1994; Omiecinski et al., 2000). In vitro, EPHX1 activity is increased (about 40%) when associated with the histidine product, probably because of altered protein stability (Hassett et al., 1994). The NQO1 P187S variant resulting from C-to-T substitution leads to reduced enzyme function (Moran et al., 1999; Traver et al., 1997) and thus, presumably, less protection against oxidative damage. We examined the effects of these metabolic gene variants in a parallel comparison of three major categories of malignant and benign brain tumors, namely the gliomas, meningiomas, and acoustic neuromas. Although we selected genes according to their possible relevance to metabolism of PAHs and other aromatic hydrocarbons, the substrate specificity is quite broad, and it is unclear to what extent the selected genes reflect a coherent pathway. Nevertheless, this exploratory approach was considered appropriate, given the dearth of knowledge about causes of brain tumors.
- Published
- 2006
25. Delta-aminolevulinic acid dehydratase polymorphism and risk of brain tumors in adults
- Author
-
Meredith Yeager, Robert G. Selker, Howard A. Fine, William R. Shapiro, Nathaniel Rothman, Preetha Rajaraman, Peter D. Inskip, Peter McL. Black, and Brian S. Schwartz
- Subjects
Adult ,Male ,tumor ,Health, Toxicology and Mutagenesis ,brain ,meningioma ,polymorphism ,Environmental Medicine ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Sex Factors ,Genotype ,Porphobilinogen ,otorhinolaryngologic diseases ,case–control ,Medicine ,Toxicokinetics ,Humans ,Genetic Predisposition to Disease ,Asparagine ,Allele ,Transversion ,Aged ,Genetics ,Aged, 80 and over ,Polymorphism, Genetic ,business.industry ,Brain Neoplasms ,Research ,Public Health, Environmental and Occupational Health ,Arizona ,ALAD ,Porphobilinogen Synthase ,Environmental Exposure ,Middle Aged ,Pennsylvania ,Molecular biology ,3. Good health ,Enzyme binding ,chemistry ,Massachusetts ,030220 oncology & carcinogenesis ,Dehydratase ,Case-Control Studies ,Female ,business ,030217 neurology & neurosurgery - Abstract
The ALAD gene codes for the enzyme δ -aminolevulinic acid dehydratase (ALAD), which catalyzes the second step of heme synthesis involving the condensation of two molecules of aminolevulinic acid (ALA) to form porphobilinogen. The most commonly studied polymorphism in the gene, ALAD G177C (dbSNP ID: rs1800435) contains a G-to-C transversion at position 177 of the coding region, resulting in the substitution of asparagine for lysine. ALAD G177C has two codominant alleles: ALAD1 and ALAD2 (Battistuzzi et al. 1981), with an ALAD2 allele prevalence of approximately 10% (range, 6–20%) in Caucasian populations, 3–11% in Asian populations, and 3% in African-American populations (Kelada et al. 2001). Although ALAD can be inhibited by a variety of chemicals, including lead, trichloroethylene, bromobenzene, and styrene (Fujita et al. 2002), polymorphic differences in enzyme binding or chemical uptake have been examined most extensively for lead. On average, individuals with the ALAD2 allele have higher blood lead levels than do ALAD1 homozygotes, probably due to tighter binding of lead by the ALAD2 enzyme (Alexander et al. 1998; Bergdahl et al. 1997; Fleming et al. 1998; Hsieh et al. 2000; Shen et al. 2001; Wetmur et al. 1991; Ziemsen et al. 1986). Previous studies in animals and humans indicate that exposure to lead may increase the risk of brain tumors [International Agency for Research on Cancer (IARC) 1987; Silbergeld 2003; Steenland and Boffetta 2000], particularly meningioma (Cocco et al. 1999; Hu et al. 1999; Navas-Acien et al. 2002). Given that the ALAD G177C polymorphism affects the toxicokinetics of lead in the body, and that exposure to lead may increase the risk of adult brain tumors, we postulated a possible association of ALAD G177C genotype and risk of intracranial tumors of the brain and nervous system (hereafter referred to as brain tumors). Analyses were conducted using data from a hospital-based case–control study of brain tumors conducted by the National Cancer Institute (NCI) between 1994 and 1998.
- Published
- 2005
26. Reproductive and hormonal factors and risk of brain tumors in adult females
- Author
-
Robert G. Selker, Elizabeth E. Hatch, William R. Shapiro, Martha S. Linet, Peter McL. Black, Howard A. Fine, Peter D. Inskip, and Jianying Zhang
- Subjects
Adult ,Risk ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Lower risk ,Risk Factors ,Glioma ,Internal medicine ,medicine ,Odds Ratio ,Humans ,Hormone metabolism ,Risk factor ,Aged ,Aged, 80 and over ,Menarche ,Obstetrics ,business.industry ,Brain Neoplasms ,Case-control study ,Odds ratio ,Middle Aged ,medicine.disease ,Hormones ,Menopause ,Endocrinology ,Oncology ,Case-Control Studies ,Female ,business ,Meningioma ,Contraceptives, Oral - Abstract
Causes of brain tumors are largely unknown, and there is an urgent need to identify possible risk factors. Several observations point to a possible role of reproductive hormones, but few epidemiologic studies have examined whether reproductive factors, such as age at menarche and parity, are associated with brain tumor risk. We conducted a multi-center case-control study of newly diagnosed glioma (n = 212) and meningioma (n = 151) and frequency-matched controls (n = 436) in women from hospitals in Phoenix, Arizona; Boston, Massachusetts; and Pittsburgh, Pennsylvania between 1994 and 1998. Research nurses interviewed patients regarding potential risk factors for brain tumors, including reproductive factors and hormone use. Unconditional logistic regression analyses were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Risk of glioma increased with older age at menarche [OR = 1.90 (95% CI = 1.09-3.32) for age at menarche > or =14 vs.
- Published
- 2004
27. Cancer in first-degree relatives and risk of glioma in adults
- Author
-
Deirdre A, Hill, Peter D, Inskip, William R, Shapiro, Robert G, Selker, Howard A, Fine, Peter M, Black, and Martha S, Linet
- Subjects
Adult ,Male ,Heterozygote ,Adolescent ,Brain Neoplasms ,Incidence ,Glioma ,Middle Aged ,Risk Assessment ,Survival Analysis ,Pedigree ,Age Distribution ,Logistic Models ,Reference Values ,Case-Control Studies ,Confidence Intervals ,Odds Ratio ,Humans ,Female ,Genetic Predisposition to Disease ,Sex Distribution ,Aged ,Probability ,Retrospective Studies - Abstract
Relatively few studies have examined glioma risk in relation to history of cancer in first-degree relatives. We sought to describe such risks in a large hospital-based case-control study. Histologically confirmed incident adult glioma cases (n = 489) were identified at three regional referral hospitals between June 1994 and August 1998. Controls (n = 799) admitted to the same hospitals for nonmalignant conditions were frequency-matched on age, sex, race/ethnicity, hospital, and proximity of residence to hospital. Participants received a personal interview, including questions regarding cancer in family members. Odds ratios (ORs) were calculated to estimate the risk of glioma associated with a history of cancer in a first-degree relative using conditional logistic regression and compared with standardized incidence ratios among relatives of cases versus relatives of controls. Among participants reporting a family history of a brain cancer or a brain tumor, risk of glioma was 1.6 [95% confidence interval (CI), 0.5-5.3; n = 5] and 3.0 (95% CI, 0.9-10.8; n = 7), respectively, in comparison with those without such family histories. Participants who had a family history of stomach (OR, 2.2; 95% CI, 1.0-4.6), colon (OR, 1.4; 95% CI, 0.9-2.2), or prostate cancer (OR, 2.1; 95% CI, 1.1-3.8) or Hodgkin disease (OR, 2.4; 95% CI, 0.9-6.3) had an increased glioma risk. OR estimates were similar to the ratios of standardized incidence ratios for cancer in relatives of cases versus controls. Shared environmental or genetic factors in families may influence glioma risk. Our findings suggest that individuals with a family history of specific cancers other than glioma may have an increased glioma risk.
- Published
- 2003
28. Clinical studies of photodynamic therapy for malignant brain tumors: facial nerve palsy after temporal fossa photoillumination
- Author
-
Tim Fullagar, Robert A. Fenstermaker, Brian C. Wilson, Robert G. Selker, Arjen Bogaards, Judith Abrams, Paul J. Muller, Lothar Lilge, and Abhay Varma
- Subjects
medicine.medical_specialty ,Palsy ,Fossa ,biology ,business.industry ,Brain tumor ,medicine.disease ,biology.organism_classification ,Lower motor neuron ,Facial nerve ,Facial paralysis ,Skull ,medicine.anatomical_structure ,medicine ,Radiology ,Temporal fossa ,business - Abstract
In two randomized prospective studies of brain tumor PDT more than 180 patients have been accrued. At the Toronto site we recognized two patients who developed a lower motor neuron (LMN) facial paralysis in the week following the PDT treatment. In both cases a temporal lobectomy was undertaken and the residual tumor cavity was photo-illuminated. The surface illuminated included the temporal fossa floor, thus potentially exposing the facial nerve to the effect of PDT. The number of frontal, temporal, parietal, and occipital tumors in this cohort was 39, 24, 12 and 4, respectively. Of the 24 temporal tumors 18 were randomized to Photofrin-PDT. Of these 18 a temporal lobectomy was carried out exposing the middle fossa floor as part of the tumor resection. In two of the 10 patients where the lobectomy was carried out and the fossa floor was exposed to light there occurred a postoperative facial palsy. Both patients recovered facial nerve function in 6 and 12 weeks, respectively. 46 J/cm2 were used in the former and 130 J/cm2 in the latter. We did not encounter a single post-operative LMN facial plasy in the 101 phase 2 patients treated with Photofrin-PDT. Among 688 supratentorial brain tumor operations in the last decade involving all pathologies and all locations no case of early post-operative LMN facial palsy was identified in the absence of PDT. One further patient who had a with post-PDT facial palsy was identified at the Denver site. Although it is possible that these patients had incidental Bell's palsy, we now recommend shielding the temporal fossa floor during PDT.
- Published
- 2003
29. Handedness and risk of brain tumors in adults
- Author
-
Peter D, Inskip, Robert E, Tarone, Alina V, Brenner, Howard A, Fine, Peter M, Black, William R, Shapiro, Robert G, Selker, and Martha S, Linet
- Subjects
Adult ,Male ,Risk ,Brain Neoplasms ,Glioma ,Neuroma, Acoustic ,Middle Aged ,Functional Laterality ,United States ,Logistic Models ,Pregnancy ,Case-Control Studies ,Prenatal Exposure Delayed Effects ,Confidence Intervals ,Meningeal Neoplasms ,Odds Ratio ,Humans ,Female ,Meningioma ,Aged - Abstract
The objective of this study was to evaluate the relation between handedness, and the risk of malignant and benign brain tumors. Handedness has been hypothesized to serve as a behavioral marker of prenatal hormonal exposures or other factors that influence subsequent cancer risk. A case-control study was conducted at hospitals in three United States cities between 1994 and 1998. The cases were adult patients newly diagnosed with glioma (n = 489), meningioma (n = 197), or acoustic neuroma (n = 96), and the 799 frequency-matched controls were patients admitted to the same hospitals for a variety of nonmalignant conditions. Handedness was determined by interview. Unconditional logistic regression was used to estimate odds ratios (ORs) and calculate 95% confidence intervals (CIs). Persons who described themselves as left-handed or ambidextrous appeared to be at reduced risk of glioma relative to those who described themselves as right-handed (OR, 0.7; 95% CI, 0.5-0.9). The association was similar for men and women, and for left-sided and right-sided tumors. Neither meningioma (OR, 0.9; CI, 0.6-1.5) nor acoustic neuroma (OR, 0.9; CI, 0.5-1.7) showed significant associations with handedness. These findings require confirmation but raise the possibility that early neurodevelopmental events or genetic factors related to handedness also influence the risk of glioma among adults.
- Published
- 2003
30. Laterality of brain tumors
- Author
-
Robert G. Selker, Robert E. Tarone, Elizabeth E. Hatch, Timothy C. Wilcosky, Howard A. Fine, Martha S. Linet, William R. Shapiro, Jay S. Loeffler, Peter D. Inskip, and Peter McL. Black
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Pathology ,Adolescent ,Epidemiology ,Acoustic neuroma ,Functional Laterality ,Meningioma ,Aphasia ,Glioma ,Internal medicine ,otorhinolaryngologic diseases ,medicine ,Humans ,neoplasms ,Demography ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,Brain Neoplasms ,Case-control study ,Magnetic resonance imaging ,Neuroma, Acoustic ,Middle Aged ,medicine.disease ,Neuroma ,Magnetic Resonance Imaging ,nervous system diseases ,Case-Control Studies ,Laterality ,Female ,sense organs ,Neurology (clinical) ,medicine.symptom ,business ,Tomography, X-Ray Computed - Abstract
Tumor laterality was evaluated with respect to presenting symptoms and demographic factors among 489 adults with histologically confirmed glioma (354 high-grade, 135 low-grade), 197 with meningioma, and 96 with acoustic neuroma. The ratio of left-sided to right-sided tumors did not differ significantly from 1.00 for any of the major tumor types. Low-grade glioma and meningioma occurred nonsignificantly more often on the left side, whereas high-grade glioma and acoustic neuroma occurred nonsignificantly more often on the right side. Aphasia or mental status changes were significantly more common among glioma patients with tumors on the left side than among those with tumors on the right side. Associations between tumor laterality and symptoms may influence the probability or timing of diagnosis, possibly differentially by marital status.
- Published
- 2003
31. Polio vaccination and risk of brain tumors in adults: no apparent association
- Author
-
Alina V, Brenner, Martha S, Linet, Robert G, Selker, William R, Shapiro, Peter M, Black, Howard A, Fine, and Peter D, Inskip
- Subjects
Adult ,Male ,Brain Neoplasms ,Statistics as Topic ,Brain ,Glioma ,Neuroma, Acoustic ,Middle Aged ,United States ,Risk Factors ,Case-Control Studies ,Poliovirus Vaccine, Oral ,Humans ,Female ,Treatment Failure ,Meningioma - Published
- 2003
32. Genetic polymorphisms in GSTM1, -P1, -T1, and CYP2E1 and the risk of adult brain tumors
- Author
-
Anneclaire J, De Roos, Nat, Rothman, Peter D, Inskip, Martha S, Linet, William R, Shapiro, Robert G, Selker, Howard A, Fine, Peter M, Black, Gary S, Pittman, and Douglas A, Bell
- Subjects
Adult ,Genetic Markers ,Male ,Risk ,Polymorphism, Genetic ,Genotype ,Brain Neoplasms ,Incidence ,Cytochrome P-450 CYP2E1 ,Glioma ,Neuroma, Acoustic ,Middle Aged ,United States ,Isoenzymes ,Glutathione S-Transferase pi ,Odds Ratio ,Humans ,Female ,Genetic Predisposition to Disease ,Meningioma ,Aged ,Glutathione Transferase - Abstract
GST and CYP2E1 genes are involved in metabolism of several compounds (e.g., solvents) that may play a role in brain cancer etiology. We evaluated associations between polymorphisms in these genes and adult brain tumor incidence. Cases were 782 patients with brain tumors diagnosed from 1994 to 1998 at three United States hospitals. Controls were 799 patients admitted to the same hospitals for nonmalignant conditions. DNA was extracted from blood samples that had been collected from 1277 subjects (80% of all subjects; 604 controls; 422 gliomas, 172 meningiomas, and 79 acoustic neuromas), and genotyping was successfully conducted for GSTM1 null, GSTT1 null, GSTP I105V, GSTP A114V, CYP2E1 RsaI, and CYP2E1 Ins96. The GSTP1 105 Val/Val genotype was associated with increased glioma incidence [odds ratio (OR), 1.8; 95% confidence limits (CLs), 1.2, 2.7], with the estimated effect following a trend of increasing magnitude by number of variant alleles (Ile/Ile: OR, 1.0; Ile/Val: OR, 1.3; Val/Val: OR, 2.1). The CYP2E1 RsaI variant was weakly associated with glioma (OR, 1.4; 95% CL, 0.9, 2.4) and acoustic neuroma (OR, 2.3; 95% CL, 1.0, 5.3), with some indication of stronger associations among younger subjects. Estimated effects of the gene variants differed by glioma subtype. There was evidence of supermultiplicativity of the joint effect of GSTP1 I105V and CYP2E1 RsaI variants on both glioma and acoustic neuroma, even following adjustment of estimates toward a common prior distribution using hierarchical regression models. Previously reported associations between the GSTT1 null genotype and overall glioma incidence were not replicated, but an association with meningioma was observed (OR, 1.5; 95% CL, 1.0, 2.3). These findings may provide clues to both genetic and environmental determinants of brain tumors.
- Published
- 2003
33. Clinical studies of photodynamic therapy for malignant brain tumors: Karnofsky score and neurological score in patients with recurrent gloms treated with Photofrin PDT
- Author
-
Tim Fullagar, Lothar Lilge, Victor X. D. Yang, Abhay Varma, Robert A. Fenstermaker, Paul J. Muller, Arjen Bogaards, Fred W. Hetzel, Judith Abrams, Brian C. Wilson, Qun Chen, and Robert G. Selker
- Subjects
medicine.medical_specialty ,Chemotherapy ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Urology ,Brain tumor ,Neurological examination ,Photodynamic therapy ,Recurrent Glioma ,medicine.disease ,Surgery ,Glioma ,medicine ,Karnofsky score ,In patient ,business - Abstract
In our previous phase II studies we treated 112 patients with malignant brain tumors with 2-mg/kg Photofrin i.v. and intra-operative cavitary PDT. We concluded that PDT was safe in patients with newly diagnosed or recurrent supratentorial malignant gliomas. Pathology, performance grade and light dose were significantly related to survival time. In selected patients when an adequate light dose was used survival time improved. The surgical mortality rate was less than 3%. [spie 2000] We have initiated two randomized prospective trials - the first, to determine if the addition of PDT to standard therapy [surgery, radiation and/or chemotherapy] prolongs the survival of patients with newly diagnosed malignant astrocytic tumors; and the second, to determine whether high light dose PDT [120 J/cm2] is superior to low light dose PDT [40 J/cm2] in patients with recurrent malignant astrocytic tumors. To date, 158 patients have been recruited - 72 to the newly diagnosed malignant glioma study and 86 to the recurrent glioma study. In the recurrent glioma study we compared the pre-operative KS and elements of the neurological examination [speech function, visual fields, cognitive function, sensory examination and gait] to the post-operative examinations at hospital discharge. The means were compared by paired student-t test. The KS in 86 of 88 patients with recurrent gliomas were assessable. The mean [s.d.] preoperative and post-operative KS were 82+/- 14 and 79+/- 17, respectively [p=0.003]. The mean decline in KS, although statistically significant, was small and of no clinical importance. The median Karnofsky score changed from 90 to 80. The KS improved in 8 patients; their post-operative average length of stay (alos) was =9.7 days. There was no change in 47 [alos=8.3], a decline of 10 points in 24 [aloc=13.4] and declined by more than 10 points in 7 [alos=23.3]. Three of these 7 patients who had a decline of >10 points improved in follow-up but did not reach their preoperative KS. The data were not available in 2. Elements of the preoperative and discharge neurological examination were assigned a score and compared by a paired t-test. There was a statistically insignificant improvement in the neurological score. A small but statistically significant decline in Karnofsky score was identified post-operatively in these recurrent tumor patients. Their hospital average length of stay increased with declining Karnofsky score. These prospective clinical observations confirmed our previous conclusion that brain tumor PDT was safe. The clinical studies are supported in part by grant CA 43892 awarded by DHHS/NIH/NCI.© (2002) COPYRIGHT SPIE--The International Society for Optical Engineering. Downloading of the abstract is permitted for personal use only.
- Published
- 2002
34. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine
- Author
-
Robert G, Selker, William R, Shapiro, Peter, Burger, Margaret S, Blackwood, Vincent C, Arena, John C, Gilder, Mark G, Malkin, John J, Mealey, John H, Neal, Jeffrey, Olson, James T, Robertson, Gene H, Barnett, Stephen, Bloomfield, Robert, Albright, Fred H, Hochberg, Emile, Hiesiger, and Sylvan, Green
- Subjects
Male ,Quality Assurance, Health Care ,Radiotherapy ,Brain Neoplasms ,Brachytherapy ,Dose-Response Relationship, Radiation ,Pilot Projects ,Glioma ,Middle Aged ,Carmustine ,Combined Modality Therapy ,Survival Analysis ,Neurosurgical Procedures ,Humans ,Female ,Antineoplastic Agents, Alkylating - Abstract
The objective of the Brain Tumor Cooperative Group NIH Trial 87-01 trial was to investigate the effect of additional implanted radiation therapy in newly diagnosed patients with pathologically confirmed malignant gliomas.The study involved a randomized comparison of surgery, external beam radiotherapy, and carmustine (BCNU) versus surgery, external beam therapy, interstitial radiotherapy boost, and BCNU in newly diagnosed malignant gliomas. (125)I was chosen as best suited for this effort because it allowed preimplantation planning and postimplantation quality assurance review. Two hundred ninety-nine patients met the eligibility criteria and were randomized into the two arms of the study between December 1987 and April 1994. Follow-up continued for an additional 3 years. Twenty-nine patients were identified as having committed protocol violations and were excluded, resulting in 270 subjects in the Valid Study Group. One hundred thirty-seven patients received external beam radiation and BCNU, and 133 underwent the (125)I implantation plus external beam radiation and BCNU therapy.The overall median survival for the Valid Study Group was 64.3 weeks. The median survival for patients receiving additional therapy of (125)I was 68.1 weeks, and median survival for those receiving only external beam radiation and BCNU was 58.8 weeks. The cumulative proportion surviving between the two treatment groups was not statistically significantly different (log-rank test, P = 0.101). As in other studies in the literature, age, Karnofsky score, and pathology were predictors of mortality. Additional analyses incorporating an adjustment for these prognostic variables, either in a stratified analysis or Cox proportional hazards model, did not result in statistically significant differences in the cumulative proportion of patients surviving between the two treatment groups.We conclude that there is no long-term survival advantage of increased radiation dose with (125)I seeds in newly diagnosed glioma patients.
- Published
- 2001
35. Photofrin photodynamic therapy for malignant brain tumors
- Author
-
Brian C. Wilson, Robert A. Fenstermaker, Judith Abrams, Paul J. Muller, Qun Chen, Fred W. Hetzel, Victor X. D. Yang, Robert G. Selker, Lothar Lilge, and Tim Fullagar
- Subjects
Oncology ,Mixed Glioma ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Brain tumor ,Photodynamic therapy ,Recurrent Glioma ,medicine.disease ,Surgery ,Radiation therapy ,Clinical trial ,Internal medicine ,medicine ,business ,Glioblastoma - Abstract
In a phase II trial we treated more than 100 patients with malignant brain tumors with 2-mg/kg Photofrin iv. and intraoperative cavitary PDT. We concluded that PDT was safe in patients with newly diagnosed or recurrent supratentorial malignant gliomas. Regression analysis showed that pathology, performance grade and light dose were significantly related to survival time. We identified a prolongation of survival in selected patients when an adequate light dose was used. The surgical mortality rate was less than 3%. We have initiated two randomized prospective trials - the first, to determine if the addition of PDT to standard therapy [surgery, radiation and/or chemotherapy] prolongs the survival of patients with newly diagnosed malignant astrocytic tumors; and the second, to determine whether high light dose PDT [120 J/cm2] is superior to low light dose PDT [40 J/cm2] in patients with recurrent malignant astrocytic tumors. In the first 20 months of these clinical studies, 90 patients have been recruited. There were 52 in the recurrent study and 37 in the newly diagnosed study. 64% of the tumors were glioblastoma and 23% malignant astrocytoma or malignant mixed glioma. In the trial of newly diagnosed tumors 17 were randomized to surgery with a mean age of 58 ! 2.9 [sem] and 20 to surgery plus PDT with a mean age of 54 ! 2.5. In recurrent glioma trial 26 were randomized to low light dose PDT [mean age 48.1 ! 2.7] and 26 to high light dose [age 52 ! 2.7]. An update of our phase 2 data and a description of brain tumor PDT techniques is presented below. The clinical studies are supported in part by grant CA 43892 awarded by DHHS/NIH/NCI.
- Published
- 2001
36. Cellular-telephone use and brain tumors
- Author
-
Robert E. Tarone, Jay S. Loeffler, William R. Shapiro, Robert G. Selker, Howard A. Fine, Timothy C. Wilcosky, Martha S. Linet, Peter McL. Black, Peter D. Inskip, and Elizabeth E. Hatch
- Subjects
Oncology ,Adult ,Male ,Risk ,medicine.medical_specialty ,Radio Waves ,Acoustic neuroma ,Central nervous system disease ,Meningioma ,Glioma ,Internal medicine ,Epidemiology ,medicine ,Meningeal Neoplasms ,Humans ,Microwaves ,Aged ,Aged, 80 and over ,business.industry ,Brain Neoplasms ,Case-control study ,General Medicine ,Neuroma, Acoustic ,Middle Aged ,medicine.disease ,Neuroma ,Surgery ,Telephone ,Socioeconomic Factors ,Relative risk ,Case-Control Studies ,Female ,business - Abstract
Concern has arisen that the use of hand-held cellular telephones might cause brain tumors. If such a risk does exist, the matter would be of considerable public health importance, given the rapid increase worldwide in the use of these devices.We examined the use of cellular telephones in a case-control study of intracranial tumors of the nervous system conducted between 1994 and 1998. We enrolled 782 patients through hospitals in Phoenix, Arizona; Boston; and Pittsburgh; 489 had histologically confirmed glioma, 197 had meningioma, and 96 had acoustic neuroma. The 799 controls were patients admitted to the same hospitals as the patients with brain tumors for a variety of nonmalignant conditions.As compared with never, or very rarely, having used a cellular telephone, the relative risks associated with a cumulative use of a cellular telephone for more than 100 hours were 0.9 for glioma (95 percent confidence interval, 0.5 to 1.6), 0.7 for meningioma (95 percent confidence interval, 0.3 to 1.7), 1.4 for acoustic neuroma (95 percent confidence interval, 0.6 to 3.5), and 1.0 for all types of tumors combined (95 percent confidence interval, 0.6 to 1.5). There was no evidence that the risks were higher among persons who used cellular telephones for 60 or more minutes per day or regularly for five or more years. Tumors did not occur disproportionately often on the side of head on which the telephone was typically used.These data do not support the hypothesis that the recent use of hand-held cellular telephones causes brain tumors, but they are not sufficient to evaluate the risks among long-term, heavy users and for potentially long induction periods.
- Published
- 2001
37. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
- Author
-
N. Yue, R Fredericks, Robert G. Selker, Raymond J. Hohl, Michael Glantz, Michael D. Prados, Michael Brada, W. K. A. Yung, Nicholas A. Vick, David Osoba, R. Rampling, Janet M. Bruner, Jeffrey J. Olson, Peter C. Phillips, Karen Fink, Alexander M. Spence, Henry S. Friedman, Harry S. Greenberg, Robert E. Albright, William R. Shapiro, S Zaknoen, and Victor A. Levin
- Subjects
Oncology ,Male ,Cancer Research ,Time Factors ,medicine.medical_treatment ,Phases of clinical research ,temozolomide ,Procarbazine ,Recurrence ,Cancer ,Brain Neoplasms ,Regular Article ,Middle Aged ,Prognosis ,Alkylating ,Dacarbazine ,6.1 Pharmaceuticals ,Public Health and Health Services ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,Clinical Trials and Supportive Activities ,Oncology and Carcinogenesis ,Antineoplastic Agents ,Gliosarcoma ,Disease-Free Survival ,glioblastoma multiforme ,Rare Diseases ,Clinical Research ,Internal medicine ,medicine ,Humans ,Oncology & Carcinogenesis ,Adverse effect ,Lung cancer ,Antineoplastic Agents, Alkylating ,Survival analysis ,Aged ,Chemotherapy ,procarbazine ,Temozolomide ,business.industry ,Neurosciences ,Evaluation of treatments and therapeutic interventions ,malignant glioma ,medicine.disease ,Surgery ,Brain Disorders ,Brain Cancer ,Quality of Life ,business ,Glioblastoma - Abstract
A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m2/day or 150 mg/m2/day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m2/day or 125 mg/m2/day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity. © 2000 Cancer Research Campaign
- Published
- 2000
38. Clinical trials of photodynamic therapy of malignant brain tumors
- Author
-
Robert A. Fenstermaker, Mike H. Hitchcock, Robert G. Selker, Lothar Lilge, Victor X. D. Yang, T. Fullager, Judith Abrams, Brian C. Wilson, Fred W. Hetzel, Qun Chen, and Paul J. Muller
- Subjects
Mixed Glioma ,Chemotherapy ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Brain tumor ,Photodynamic therapy ,Recurrent Glioma ,Interim analysis ,medicine.disease ,Surgery ,Clinical trial ,medicine ,Porfimer sodium ,Radiology ,business ,medicine.drug - Abstract
Photodynamic therapy [PDT] is a local treatment for malignant tumors. In a phase 2 trial in patients with supratentorial gliomas treated with 2 mg/kg Photofrin i.v. and intraoperative cavitary PDT, we were able to conclude that PDT was safe in patients with either newly diagnosed or recurrent supratentorial malignant gliomas. There appears to be prolongation of survival in selected patients when an adequate light dose is used. The surgical mortality rate was less than 3%. We have initiated two randomized prospective trials - the first to determine if the addition of PDT to standard therapy [surgery, radiation and/or chemotherapy] prolongs the survival of patients with newly diagnosed malignant astrocytic tumors; and the second, to determine whether high light dose PDT [120 J/cm 2 ] is superior to low light dose PDT [40 J/cm 2 ] in patients with recurrent malignant astrocytic tumors. In the first 12 month 60 patients [36 males and 24 females] have been recruited to these phase III trials. There were 37 in the recurrent study and 23 in the newly diagnosed study. 64% of the tumors were glioblastoma and 23% malignant astrocytoma or malignant mixed glioma. In the trial of newly diagnosed tumors 12 were randomized to surgery with a mean age of 63.2 ± 4.0 [sem] and 11 to surgery plus PDT with a mean age of 53.4 ± 3.1. In recurrent glioma trial 19 were randomized to low light dose PDT [mean age 48.1 ± 2.5] and 18 to high light dose [age 46.4 ± 2.9]. An interim analysis will be undertaken at the time of 25 deaths in each of the studies. A multispectral digital camera has been developed for the purpose of fluorescence detection; we have used the device in PDT brain tumor cases. This investigation is supported in part by grant CA 43892 awarded by DHHS/NIH/NCI.
- Published
- 2000
39. Commentary
- Author
-
Robert G. Selker
- Subjects
Surgery ,Neurology (clinical) - Published
- 2005
40. On the development of an interstitial radiation protocol for a multicenter consortium. Experience with permanent low-dose rate and temporary high-dose rate 125I implants in 'failed' and 'newly diagnosed' glioblastoma patients: quality assurance methodology and a possible future adjuvant for therapeutic enhancement
- Author
-
Melvin Deutsch, Margaret S. Eddy, Robert G. Selker, Vincent C. Arena, and Peter C. Burger
- Subjects
Cancer Research ,medicine.medical_specialty ,Quality Assurance, Health Care ,medicine.medical_treatment ,Newly diagnosed ,Iodine Radioisotopes ,Recurrence ,Medicine ,Humans ,Protocol (science) ,business.industry ,Brain Neoplasms ,Infusion Pumps, Implantable ,Middle Aged ,medicine.disease ,Surgery ,Radiation therapy ,Survival Rate ,Catheter ,Neurology ,Oncology ,Research Design ,Radiotherapy, Adjuvant ,Neurology (clinical) ,Implant ,business ,Glioblastoma ,Adjuvant ,Quality assurance - Abstract
Three interstitial implant trial groups (one permanent low-dose rate 125I and two temporary high-dose rate 125I implants) in glioblastoma patients ('newly diagnosed' and 'failed') were compared to non-randomized similar control groups for efficacy. The results formed the basis for the BTCG 87-01 national implant trial. The 'pilot' trial demonstrated: 1) the effectiveness of a temporary high-dose rate 125I implant in 'failed' and 'newly diagnosed' patients; 2) the ability of a multicenter consortium to adhere to a standard protocol; 3) a methodology to insure quality assurance; and 4) the possibility of the future adjuvant application of hyperthermia using a single catheter system.
- Published
- 1995
41. The erythrocyte sedimentation rate: an interface between science and the law
- Author
-
Bruce L. Wilder and Robert G. Selker
- Subjects
medicine.medical_specialty ,Time Factors ,medicine.diagnostic_test ,business.industry ,Erythrocyte sedimentation ,Malpractice ,Osteomyelitis ,Blood Sedimentation ,Middle Aged ,Surgery ,Intervertebral disk ,Postoperative Complications ,Elevated sedimentation rate ,Internal medicine ,Erythrocyte sedimentation rate ,Cardiology ,Medicine ,Humans ,Female ,Neurology (clinical) ,skin and connective tissue diseases ,business ,Disk space ,Intervertebral Disc Displacement - Abstract
Excerpts from the deposition of a medical expert appearing for a female plaintiff in a malpractice action dealing with a postoperative disk space infection are presented. Much of the issue centered about the erythrocyte sedimentation (ESR) rate 4 months postdisk surgery (ESR = 23 mm/hr). The expert testified that the ESR will, after an initial rise, return to normal levels in the face of progressive symptomatology and inflammatory bone change. The pertinent literature cited indicates that the elevated sedimentation rate in infection not only persists, but escalates and remains in an elevated state until appropriate therapy is instituted.
- Published
- 1995
42. Results of a randomized trial comparing intra-arterial cisplatin and intravenous PCNU for the treatment of primary brain tumors in adults: Brain Tumor Cooperative Group trial 8420A
- Author
-
Fred H. Hochberg, Robert G. Selker, Peter C. Burger, William R. Shapiro, Sylvan B. Green, Joseph Ransohoff, John C. VanGilder, John Mealey, Ronald F. Young, M. Stephen Mahaley, James T. Robertson, and Emile M. Hiesiger
- Subjects
Oncology ,Adult ,Cancer Research ,medicine.medical_specialty ,Aging ,Neurology ,medicine.medical_treatment ,Brain tumor ,Antineoplastic Agents ,Nitrosourea Compounds ,law.invention ,Central nervous system disease ,Randomized controlled trial ,law ,Internal medicine ,Glioma ,medicine ,Humans ,Karnofsky Performance Status ,Antineoplastic Agents, Alkylating ,Survival analysis ,Aged ,Cisplatin ,Chemotherapy ,business.industry ,Supratentorial Neoplasms ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Survival Analysis ,Injections, Intra-Arterial ,Anesthesia ,Injections, Intravenous ,Disease Progression ,Neurology (clinical) ,business ,medicine.drug - Abstract
To test the efficacy of intra-arterial (IA) cisplatin versus intravenous (IV) PCNU for treating primary brain tumors, in a randomized trial (Brain Tumor Cooperative Group [BTCG] Trial 8420A).311 adult patients (ages 19-79 years; median 45) with supratentorial tumors (confirmed histologically) were randomized by nine participating institutions. Patients were required to have completed radiotherapy (4500-6020 cGy to the tumor bed) before randomization. Patients were stratified as either nonprogressive (clinically and radiologically stable) or progressive. Results were analyzed for the 311 patients in the randomized population (RP), and for the 281 patients in the Valid Study Group (VSG) meeting protocol eligibility requirements. 56% of patients in the VSG had glioblastoma multiforme, 33% had other malignant glioma, and 11% had low-grade glioma. 64% were stratified as progressive. 12% had received prior chemotherapy.The group randomized to PCNU had the longer survival (p = 0.06 for the RP, p = 0.07 for the VSG). In the VSG, median survival was 10 months for the cisplatin group, 13 months for the PCNU group. The difference between treatment groups was significant (por = 0.02) when adjusted for important prognostic factors. PCNU lead to greater hematotoxicity; cisplatin lead to greater renal toxicity and some ototoxicity. Some cisplatin patients experienced complications associated with IA administration, including six cases of encephalopathy.The trial showed a survival advantage to the group randomized to PCNU, although the difference was modest. Coupled with previous BTCG results, these trails suggest that PCNU is an active drug for brain tumors.
- Published
- 1995
43. Superiority of PCNU over AZQ in the treatment of primary brain tumors: results of a prospective randomized trial (81-20) by the Brain Tumor Study Group
- Author
-
M. Stephen Mahaley, David P. Byar, Robert G. Selker, Peter C. Burger, Joseph Ransohoff, Thomas A. Strike, Mark G. Malkin, William R. Shapiro, John Mealey, John C. Van Gilder, F. Stephen Vogel, David A. Pistenmaa, James T. Robertson, and Sylvan B. Green
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Randomization ,medicine.medical_treatment ,Population ,Aziridines ,Brain tumor ,Antineoplastic Agents ,Nitrosourea Compounds ,law.invention ,Randomized controlled trial ,law ,Recurrence ,Internal medicine ,medicine ,Benzoquinones ,Humans ,Prospective Studies ,education ,Child ,Survival analysis ,education.field_of_study ,Chemotherapy ,Performance status ,business.industry ,Brain Neoplasms ,Middle Aged ,medicine.disease ,Survival Analysis ,Surgery ,Radiation therapy ,Neurology ,Neurology (clinical) ,business - Abstract
A two-arm randomized clinical trial was performed to determine the efficacy of PCNU and AZQ in the treatment of de novo or recurrent primary brain tumors. An additional objective was to gather information on the administration and toxicity of these compounds, supplementing that obtained previously in phase I/II studies.During 1982 and 1983 the Brain Tumor Study Group randomized 152 adult patients with primary brain tumors to receive PCNU 75-100 mg/m2 intravenously (IV) every 8 weeks or AZQ 15 mg/m2 IV once a week for 4 weeks, every 6-8 weeks. All patients who had not received 'full dose' radiotherapy before randomization received it concurrently with the first course of protocol chemotherapy. The data were analyzed for the total randomized population (RP), and for 130 patients in the valid study group (VSG) formed by excluding 22 patients for whom the histologic diagnosis was not documented by central review.Median survival times were 11.0 months for the PCNU group and 8.4 months for the AZQ group. The difference in survival curves was statistically significant for the RP (p = 0.01) and the VSG (p = 0.02). Life-table analysis of the VSG showed estimated 2-year survivals of 34% for PCNU and 11% for AZQ. The advantage of PCNU remained significant (p = 0.006) after adjustment for histopathologic category, age, initial performance status, and interval from initial reported surgery. Myelosuppression was the principal toxicity in both groups.
- Published
- 1994
44. A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro
- Author
-
Terri Rehn, Frank T. Vertosick, Matthew P. Kristofik, Margaret S. Randall, and Robert G. Selker
- Subjects
Cancer Research ,medicine.medical_specialty ,Metabolite ,N-Desmethyltamoxifen ,Tetrazolium Salts ,chemistry.chemical_compound ,Internal medicine ,Glioma ,medicine ,Tumor Cells, Cultured ,Humans ,MTT assay ,Coloring Agents ,Protein kinase C ,Dose-Response Relationship, Drug ,business.industry ,medicine.disease ,In vitro ,Tamoxifen ,Thiazoles ,Endocrinology ,Neurology ,Oncology ,chemistry ,Cancer research ,Colorimetry ,Neurology (clinical) ,Drug Screening Assays, Antitumor ,business ,Thymidine ,medicine.drug - Abstract
Tamoxifen has been shown to inhibit the proliferation of human gliomasin vitro. This inhibition is independent of tamoxifen's known anti-estrogenic properties. Tamoxifen is an inhibitor of protein kinase C (PKC), a calcium- and phospholipid-dependent serine kinase which plays a critical role in the proliferation of certain cell lines. Gliomas overexpress PKC, and their growth rate is coupled to the level of this key enzyme. As such, the effect of tamoxifen may be mediated by its inhibitory effect on PKC. To further investigate this possibility, we compared the chemosensitivity of cultured glioma lines to both tamoxifen and N-desmethyltamoxifen (DMT). DMT is the major metabolite of tamoxifen in humans and is a ten-fold more potent inhibitor of PKC. Seven lines were tested using the standard MTT assay, which quantitates metabolically active cells colorimetrically using a tetrazolium dye. Four of the seven lines were also tested using a tritiated thymidine uptake assay. In the MTT assay, all seven lines showed significantly greater sensitivity to DMT, while three of the four lines tested in the thymidine uptake assay were more sensitive to DMT. Correlation between the two assays was good. The dose of tamoxifen required to produce a 50% inhibition of optical absorbance or thymidine uptake (ID50) was typically five- to ten-fold greater than the ID50 for DMT, approximating the relative strength of the two compounds as PKC inhibitors. In addition to providing some support for the ypothesis that triphenylethylenes inhibit gliomas via PKC inhibition, these findings have clinical significance. Levels of DMT in serum, brain and brain metastases are about twice the comparable levels of tamoxifen during chronic therapy. DMT achieved complete inhibition of all seven glioma lines at concentrations of 200 ng/ml. Levels as high as 2000 ng/g can be achieved in tumor tissue, suggesting that chronic tamoxifen therapy may have some role in the therapy of these aggressive tumors.
- Published
- 1994
45. Long-term survival after the diagnosis of malignant glioma: a series of 22 patients surviving more than 4 years after diagnosis
- Author
-
Frank T. Vertosick and Robert G. Selker
- Subjects
Mixed Glioma ,Adult ,Male ,medicine.medical_specialty ,Time Factors ,Population ,Computed tomography ,Disease ,Astrocytoma ,Glioma ,medicine ,Humans ,education ,Survival analysis ,Aged ,education.field_of_study ,Series (stratigraphy) ,medicine.diagnostic_test ,business.industry ,Brain Neoplasms ,Middle Aged ,medicine.disease ,Survival Analysis ,Surgery ,Female ,Neurology (clinical) ,Radiology ,business ,Glioblastoma ,Anaplastic astrocytoma - Abstract
Long-term survival after the diagnosis of malignant glioma is uncommon but not rare. To define better the population of patients who have extended survival with this disease, we reviewed the records of 22 of our patients who survived more than 4 years after the biopsy-proven diagnosis of anaplastic astrocytoma, malignant mixed glioma, or glioblastoma multiforme. Surprisingly, 21 of the 22 patients are still alive and being actively followed by the authors. The long-term survivors were typically young and with minimal or no functional impairment at the time of diagnosis. Survivals ranged from 4.2 to 15.8 years. The quality of survival was generally good, with the surviving patients having a mean Karnofsky Performance Score of 76. Three-quarters of the patients had no enhancement or mass effect on their most recent computed tomography scans. A review of the available literature, together with our own series, suggests that death from recurrent disease is unusual in glioma patients who survive more than 4 or 5 years.
- Published
- 1992
46. Response of low-passage human malignant gliomas in vitro to stimulation and selective inhibition of growth factor-mediated pathways
- Author
-
Robert G. Selker, R. H. Kelly, Ian F. Pollack, Margaret S. Randall, Frank T. Vertosick, and Matthew P. Kristofik
- Subjects
DNA Replication ,medicine.medical_specialty ,Platelet-derived growth factor ,medicine.medical_treatment ,Fibroblast growth factor ,Antibodies ,chemistry.chemical_compound ,Epidermal growth factor ,Internal medicine ,Glioma ,medicine ,Tumor Cells, Cultured ,Humans ,Growth Substances ,Polymyxin B ,Platelet-Derived Growth Factor ,biology ,Dose-Response Relationship, Drug ,Cell growth ,Growth factor ,DNA, Neoplasm ,medicine.disease ,Growth Inhibitors ,Trapidil ,Endocrinology ,Nerve growth factor ,chemistry ,biology.protein ,Cancer research ,Glioblastoma ,Platelet-derived growth factor receptor - Abstract
✓ The proliferation of many nonglial tumors in vitro depends on the presence of nanomolar concentrations of one or more growth factors. To define the growth factor requirements of malignant glial tumors, the authors examined the response properties of four low-passage human malignant glioma lines to the following mitogens: epidermal growth factor (EGF), acidic and basic fibroblast growth factors (FGF's), insulin-like growth factor I (IGF-1), nerve growth factor (NGF), platelet-derived growth factor (PDGF), 12-0-tetradecanoyl-13-phorbol acetate (TPA), and serum. Each of the tumors showed increased deoxyribonucleic acid (DNA) synthesis (assessed by acid-precipitable [3H]-thymidine incorporation) in response to PDGF with a maximum effect at 50 ng/ml. Three tumors responded to EGF, three to IGF-I, two to acidic FGF, two to basic FGF, and two to TPA with maximum effects at 10, 50, 1, 1, and 10 ng/ml, respectively. None of the tumors responded to NGF. In the responsive tumors, optimum concentrations of EGF, IGF, TPA, acidic FGF, and basic FGF induced, at most, a two- to fourfold increase in [3H]-thymidine incorporation, which was only 30% to 50% of the response seen in 10% serum. In contrast, PDGF increased DNA synthesis eight- to 10-fold, equaling the effect of 10% serum. Measurements of cell proliferation also demonstrated a significant response to PDGF in each of the tumors. Appropriate concentrations of an anti-PDGF neutralizing antibody inhibited baseline DNA synthesis and proliferation in the absence of added growth factors, suggesting the possible role of PDGF in autocrine stimulation of these cells. However, this antibody produced only slight inhibition of seruminduced mitogenesis. Trapidil, an agent reported to inhibit the effects of PDGF, and polymyxin B, an inhibitor of protein kinase C, strongly inhibited baseline as well as PDGF- and serum-induced mitogenesis. It is concluded that, in the malignant gliomas studied, PDGF may be acting as a dominant mitogen to enhance DNA synthesis, and may function in autocrine stimulation. However, other factors contained in serum can also contribute to cell division.
- Published
- 1991
47. Response of malignant glioma cell lines to activation and inhibition of protein kinase C-mediated pathways
- Author
-
Ian F. Pollack, Margaret S. Randall, Robert G. Selker, R. H. Kelly, Matthew P. Kristofik, and Frank T. Vertosick
- Subjects
Biology ,Glioma ,medicine ,Tumor Cells, Cultured ,Animals ,Humans ,Polymyxins ,Protein kinase A ,Protein kinase C ,Protein Kinase C ,Polymyxin B ,Platelet-Derived Growth Factor ,DNA synthesis ,Epidermal Growth Factor ,Cell growth ,Kinase ,Brain Neoplasms ,Brain ,DNA, Neoplasm ,medicine.disease ,Molecular biology ,Rats ,Chemically defined medium ,Biochemistry ,Cell culture ,Cell Division ,Thymidine - Abstract
✓ To evaluate the role of protein kinase C-mediated pathways in the proliferation of malignant gliomas, this study examined the effect of a protein kinase C (PKC)-activating phorbol ester (12-O-tetradecanoyl-13-phorbol acetate or TPA) and a protein kinase C inhibitor (polymyxin B) on deoxyribonucleic acid (DNA) synthesis of malignant glioma cells in vitro. A serum-free chemically defined medium, MCDB 105, was employed for all studies. Two established human malignant glioma cell lines (T98G and U138), two rat glioma lines (9L and C6), and two low-passage human glioma lines (obtained from surgical specimens) were studied. With the exception of the C6 line, all tumors responded in a dose-dependent fashion to nanomolar concentrations of TPA with a median effective dose that varied from 0.5 ng/ml for the U138 glioma to 1 ng/ml for the T98G glioma. At optimal concentrations (5 to 10 ng/ml), TPA produced a two- to five-fold increase in the rate of DNA synthesis (p < 0.05) as assessed by incorporation of 3H-thymidine. However, TPA had no additive effect on the mitogenic response produced by epidermal growth factor (EGF) or platelet-derived growth factor (PDGF). Inhibition of PKC using the antibiotic polymyxin B (20 µg/ml) abolished the TPA-induced mitogenic response in the five responsive lines tested. In two tumors (U138 and 9L), polymyxin B also eliminated EGF-, PDGF-, and serum-induced DNA synthesis as well as abolishing baseline DNA synthesis. These cells remained viable, however, as assessed by trypan blue exclusion; after removal of polymyxin B from the medium, they were able to resume DNA synthesis in response to TPA and serum. In the three other tumors (T98G and the two low-passage human glioma lines), growth factor-induced and serum-induced DNA synthesis were inhibited by approximately 25% to 85%. It is concluded that PKC-mediated pathways affect DNA synthesis in the human malignant glial tumors studied. The response of the glioma cells to TPA is similar to the responses seen in fetal astrocytes, but differs significantly from those reported for normal adult glial cultures. Because the response of the 9L glioma to TPA is similar to the responses seen in the human tumors, the 9L rat glioma model may prove useful for examining the role of PKC-mediated pathways in controlling glioma growth in vivo.
- Published
- 1990
48. Response of malignant glioma cell lines to epidermal growth factor and platelet-derived growth factor in a serum-free medium
- Author
-
Ian F. Pollack, Frank T. Vertosick, Robert G. Selker, Margaret S. Randall, R. H. Kelly, and Matthew P. Kristofik
- Subjects
medicine.medical_specialty ,Platelet-derived growth factor ,Cell division ,medicine.medical_treatment ,Biology ,Iodine Radioisotopes ,chemistry.chemical_compound ,Epidermal growth factor ,Internal medicine ,medicine ,Tumor Cells, Cultured ,Humans ,Growth factor receptor inhibitor ,Receptor ,Neurons ,Platelet-Derived Growth Factor ,Epidermal Growth Factor ,Brain Neoplasms ,Growth factor ,Glioma ,Culture Media ,Endocrinology ,chemistry ,Cell culture ,biology.protein ,Platelet-derived growth factor receptor ,Cell Division ,Thymidine - Abstract
✓ The use of a serum-free culture system for assessing the growth factor responsiveness of malignant glial cells is described. The mitogenic properties of epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) were examined in three human malignant glioma cell lines (T98G, U87, and U138). Each of the three had high-affinity EGF receptors and all responded in a dose-dependent fashion to physiological concentrations of EGF. These cell lines also showed a pronounced mitogenic response to PDGF which equaled or exceeded that achieved with EGF. Simultaneous stimulation with both factors produced an additive response, which approximated that obtained in medium supplemented with 10% fetal calf serum. The authors conclude that functional EGF and PDGF receptors were present in the human malignant glial tumors studied. The response of the human glioma lines to these growth factors in many respects parallels the response seen in fetal astrocytes tested under similar conditions. In contrast, the behavior of two chemically induced rat gliomas (9L and C6) differed significantly from that seen in the human lines, suggesting that the rat lines may not be entirely acceptable as models for studying the growth characteristics of human malignant glial tumors.
- Published
- 1990
49. Commentary
- Author
-
Robert G. Selker
- Subjects
Surgery ,Neurology (clinical) - Published
- 2006
50. Commentary
- Author
-
Robert G. Selker
- Subjects
Surgery ,Neurology (clinical) - Published
- 2004
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.